|
EP3153526B1
(en)
|
2008-01-31 |
2020-09-23 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
|
|
SMT202400136T1
(it)
|
2008-12-09 |
2024-05-14 |
Hoffmann La Roche |
Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t
|
|
EP3279215B1
(en)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Targeted binding agents against b7-h1
|
|
NZ599516A
(en)
|
2009-12-10 |
2013-11-29 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
WO2012178137A1
(en)
|
2011-06-24 |
2012-12-27 |
Gillies Stephen D |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US9416132B2
(en)
|
2011-07-21 |
2016-08-16 |
Tolero Pharmaceuticals, Inc. |
Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
|
|
AU2012290121B2
(en)
|
2011-08-01 |
2015-11-26 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
|
|
SMT202000561T1
(it)
|
2011-11-28 |
2021-01-05 |
Merck Patent Gmbh |
Anticorpi anti-pd-l1 e usi relativi
|
|
CN113967253A
(zh)
|
2012-05-15 |
2022-01-25 |
百时美施贵宝公司 |
通过破坏pd-1/pd-l1信号传输的免疫治疗
|
|
CN104736168B
(zh)
*
|
2012-05-31 |
2018-09-21 |
索伦托治疗有限公司 |
与pd-l1结合的抗原结合蛋白
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
SG11201408646VA
(en)
|
2012-07-06 |
2015-01-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
SG10201702421TA
(en)
|
2012-10-02 |
2017-05-30 |
Bristol Myers Squibb Co |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
|
|
CA3139031A1
(en)
|
2012-10-04 |
2014-04-10 |
Dana-Farber Cancer Institute, Inc. |
Human monoclonal anti-pd-l1 antibodies and methods of use
|
|
EP4223770A3
(en)
|
2012-11-05 |
2023-10-18 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
WO2014071358A2
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
|
BR112015012644A2
(pt)
|
2012-11-30 |
2017-12-19 |
Hoffmann La Roche |
método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
|
|
BR112015013557B1
(pt)
*
|
2012-12-11 |
2021-12-14 |
Albert Einstein College Of Medicine |
Sistema, método, método para determinar o efeito de um resíduo de aminoácido predeterminado de uma primeira proteína sobre a ligação da primeira proteína a uma segunda proteína e polipeptídeo pd-l1 mutante
|
|
AR093984A1
(es)
*
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
WO2014107873A1
(zh)
*
|
2013-01-11 |
2014-07-17 |
苏州丁孚靶点生物技术有限公司 |
用于肿瘤治疗的试剂、其用途及方法
|
|
EP3939614A1
(en)
|
2013-01-18 |
2022-01-19 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
BR122021025267B1
(pt)
|
2013-02-22 |
2023-12-05 |
Curevac Ag |
Partes de kit e composição farmacêutica compreendendo um inibidor da via de pd-1
|
|
SG10201710472PA
(en)
|
2013-02-22 |
2018-02-27 |
Curevac Ag |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
PL2964638T3
(pl)
|
2013-03-06 |
2018-01-31 |
Astrazeneca Ab |
Inhibitory chinazolinowe aktywujących zmutowanych postaci receptora epidermalnego czynnika wzrostu
|
|
WO2014165082A2
(en)
*
|
2013-03-13 |
2014-10-09 |
Medimmune, Llc |
Antibodies and methods of detection
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
US20150071910A1
(en)
*
|
2013-03-15 |
2015-03-12 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
ES2761260T3
(es)
|
2013-03-15 |
2020-05-19 |
Hoffmann La Roche |
Biomarcadores y procedimientos de tratamiento de afecciones relacionadas con PD-1 y PD-L1
|
|
KR20150139955A
(ko)
|
2013-04-09 |
2015-12-14 |
보스톤 바이오메디칼, 인크. |
암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
WO2015016718A1
(en)
|
2013-08-02 |
2015-02-05 |
Bionovion Holding B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
|
ES2675027T3
(es)
|
2013-09-06 |
2018-07-05 |
Aurigene Discovery Technologies Limited |
Derivados de 1,2,4-oxadiazol como inmunomoduladores
|
|
PT3041468T
(pt)
|
2013-09-06 |
2018-09-28 |
Aurigene Discovery Tech Ltd |
Compostos peptidomiméticos cíclicos como imunomoduladores
|
|
MX2016002971A
(es)
|
2013-09-06 |
2016-10-07 |
Aurigene Discovery Tech Ltd |
Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores.
|
|
CN112546217B
(zh)
|
2013-09-11 |
2025-04-29 |
米迪缪尼有限公司 |
用于治疗肿瘤的抗b7-h1抗体
|
|
AR097584A1
(es)
*
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
SMT202000162T1
(it)
|
2013-09-16 |
2020-05-08 |
Astrazeneca Ab |
Nanoparticelle polimeriche terapeutiche e metodi per preparare e usare le stesse
|
|
KR20160055269A
(ko)
|
2013-09-20 |
2016-05-17 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
EP3470081A1
(en)
|
2013-10-01 |
2019-04-17 |
Mayo Foundation for Medical Education and Research |
Methods for treating cancer in patients with elevated levels of bim
|
|
EP3060581A4
(en)
*
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoclonal antibodies and fragments thereof
|
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
EP3680254A1
(en)
|
2013-12-17 |
2020-07-15 |
F. Hoffmann-La Roche AG |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
|
EP3083690A1
(en)
|
2013-12-17 |
2016-10-26 |
F.Hoffmann-La Roche Ag |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
|
CA2936077C
(en)
*
|
2014-01-06 |
2020-06-30 |
Expression Pathology, Inc. |
Srm assay for pd-l1
|
|
EP3092256B1
(en)
|
2014-01-10 |
2022-05-18 |
Birdie Biopharmaceuticals Inc. |
Compounds and compositions for immunotherapy
|
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
RU2752424C2
(ru)
|
2014-02-10 |
2021-07-28 |
Мерк Патент Гмбх |
Направленное ингибирование tgf бета
|
|
CA2942039A1
(en)
*
|
2014-02-18 |
2015-08-27 |
Health Research, Inc. |
Combination therapy for hepatocellular carcinoma
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
|
KR20220126813A
(ko)
|
2014-03-14 |
2022-09-16 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
|
CN106456756B
(zh)
|
2014-05-13 |
2021-04-23 |
免疫医疗有限公司 |
用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体
|
|
BR112016026559A8
(pt)
|
2014-05-15 |
2021-07-13 |
Bristol Myers Squibb Co |
uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
CA2949327A1
(en)
*
|
2014-05-29 |
2015-12-03 |
Medimmune Limited |
Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
|
|
JP6666905B2
(ja)
|
2014-05-29 |
2020-03-18 |
スプリング バイオサイエンス コーポレーション |
Ｐｄ−ｌ１抗体及びその使用
|
|
HRP20192098T1
(hr)
|
2014-06-06 |
2020-02-21 |
Bristol-Myers Squibb Company |
Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
|
|
WO2015195163A1
(en)
*
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
CN110156892B
(zh)
*
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
|
DK3166976T3
(da)
|
2014-07-09 |
2022-04-11 |
Birdie Biopharmaceuticals Inc |
Anti-pd-l1-kombinationer til behandling af tumorer
|
|
BR112017000497B1
(pt)
|
2014-07-11 |
2023-12-26 |
Ventana Medical Systems, Inc |
Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
|
|
SG10202007111TA
(en)
|
2014-07-15 |
2020-09-29 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
US10517875B2
(en)
|
2014-07-23 |
2019-12-31 |
Mayo Foundation for Medical Engineering and Research |
Targeting DNA-PKcs and B7-H1 to treat cancer
|
|
SMT202200285T1
(it)
|
2014-08-11 |
2022-09-14 |
Acerta Pharma Bv |
Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1
|
|
HUE043847T2
(hu)
|
2014-08-28 |
2019-09-30 |
Halozyme Inc |
Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
|
|
WO2016030455A1
(en)
|
2014-08-28 |
2016-03-03 |
Medimmune Limited |
Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
EP3189080A1
(en)
*
|
2014-09-05 |
2017-07-12 |
Medimmune Limited |
Methods for identifying patients responsive to anti-pd-l1 antibody therapy using markers (cxcl9, krt8.trim29, and ifngamma)
|
|
EP3925622A1
(en)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Combination therapies
|
|
AU2015316991B2
(en)
|
2014-09-16 |
2021-04-01 |
Innate Pharma |
Neutralization of inhibitory pathways in lymphocytes
|
|
WO2016049214A1
(en)
|
2014-09-23 |
2016-03-31 |
Genentech, Inc. |
METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
|
|
AU2015329982B2
(en)
|
2014-10-10 |
2021-05-20 |
Innate Pharma |
CD73 blockade
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
WO2016061286A2
(en)
|
2014-10-14 |
2016-04-21 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
RU2744841C2
(ru)
|
2014-10-24 |
2021-03-16 |
Астразенека Аб |
Комбинация
|
|
HRP20210888T4
(hr)
|
2014-11-10 |
2024-12-06 |
Medimmune Limited |
Vezujuće molekule specifične za cd73 i njihova upotreba
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
EP4141032B1
(en)
|
2014-11-20 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
|
SMT202000413T1
(it)
|
2014-11-21 |
2020-09-10 |
Bristol Myers Squibb Co |
Anticorpi nei confronti di cd73 e loro usi
|
|
CA2968382A1
(en)
|
2014-11-21 |
2016-05-26 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
EP3227337A1
(en)
|
2014-12-05 |
2017-10-11 |
F. Hoffmann-La Roche AG |
Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists
|
|
HUE052606T2
(hu)
*
|
2014-12-09 |
2021-05-28 |
Regeneron Pharma |
Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok
|
|
CN110256558B
(zh)
|
2014-12-23 |
2023-07-04 |
百时美施贵宝公司 |
针对tigit的抗体
|
|
GB201500319D0
(en)
*
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
HK1247861A1
(zh)
|
2015-01-30 |
2018-10-05 |
President And Fellows Of Harvard College |
用於癌症治疗的肿瘤周围和肿瘤内部材料
|
|
EP3254110B1
(en)
|
2015-02-03 |
2020-03-18 |
Ventana Medical Systems, Inc. |
Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
EP4279087A3
(en)
|
2015-02-26 |
2024-01-31 |
Merck Patent GmbH |
Pd-1 / pd-l1 inhibitors for the treatment of cancer
|
|
MY194341A
(en)
|
2015-03-06 |
2022-11-29 |
Beyondspring Pharmaceuticals Inc |
Method of treating a brain tumor
|
|
MX383691B
(es)
|
2015-03-06 |
2025-03-14 |
Beyondspring Pharmaceuticals Inc |
Método de tratamiento de cáncer asociado con una mutación de ras.
|
|
DK3267984T3
(da)
|
2015-03-10 |
2022-03-07 |
Aurigene Discovery Tech Ltd |
Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer
|
|
BR112017019559B1
(pt)
*
|
2015-03-13 |
2020-08-04 |
Cytomx Therapeutics, Inc |
Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes
|
|
WO2016146143A1
(en)
|
2015-03-16 |
2016-09-22 |
Amal Therapeutics Sa |
Cell penetrating peptides and complexes comprising the same
|
|
EP3274370B1
(en)
|
2015-03-23 |
2019-11-20 |
Bayer Pharma Aktiengesellschaft |
Anti-ceacam6 antibodies and uses thereof
|
|
US11933786B2
(en)
|
2015-03-30 |
2024-03-19 |
Stcube, Inc. |
Antibodies specific to glycosylated PD-L1 and methods of use thereof
|
|
EP3277320A4
(en)
*
|
2015-03-30 |
2018-08-01 |
Stcube, Inc. |
Antibodies specific to glycosylated pd-l1 and methods of use thereof
|
|
CN107530432B
(zh)
|
2015-04-07 |
2021-04-27 |
Cytlimic公司 |
药物
|
|
CA2982657A1
(en)
*
|
2015-04-17 |
2016-10-20 |
Elsalys Biotech |
Anti-tyro3 antibodies and uses thereof
|
|
CN104830788A
(zh)
*
|
2015-05-05 |
2015-08-12 |
杨光华 |
基于hbv-hcv抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
|
|
PT3294770T
(pt)
|
2015-05-12 |
2020-12-04 |
Hoffmann La Roche |
Métodos terapêuticos e diagnósticos para o cancro
|
|
TW201705955A
(zh)
|
2015-05-14 |
2017-02-16 |
輝瑞大藥廠 |
包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法
|
|
AU2016264212B2
(en)
|
2015-05-18 |
2020-10-22 |
Sumitomo Pharma Oncology, Inc. |
Alvocidib prodrugs having increased bioavailability
|
|
US20160347848A1
(en)
|
2015-05-28 |
2016-12-01 |
Medimmune Limited |
Therapeutic combinations and methods for treating neoplasia
|
|
US20180155429A1
(en)
|
2015-05-28 |
2018-06-07 |
Bristol-Myers Squibb Company |
Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
|
|
WO2016196389A1
(en)
|
2015-05-29 |
2016-12-08 |
Bristol-Myers Squibb Company |
Treatment of renal cell carcinoma
|
|
PE20180672A1
(es)
|
2015-05-29 |
2018-04-19 |
Agenus Inc |
Anticuerpos anti-ctla-4 y metodos de uso de los mismos
|
|
HK1248773A1
(zh)
|
2015-05-29 |
2018-10-19 |
豪夫迈‧罗氏有限公司 |
用於癌症的治疗和诊断方法
|
|
KR20180013881A
(ko)
|
2015-05-29 |
2018-02-07 |
제넨테크, 인크. |
암에서의 pd-l1 프로모터 메틸화
|
|
CN108137687B
(zh)
|
2015-05-29 |
2021-10-29 |
百时美施贵宝公司 |
抗ox40抗体及其用途
|
|
CN107613980A
(zh)
|
2015-05-31 |
2018-01-19 |
源生公司 |
用于免疫疗法的组合组合物
|
|
CN107847481A
(zh)
|
2015-06-03 |
2018-03-27 |
波士顿生物医药有限公司 |
包含癌症干性抑制剂的组合物和用于治疗癌症的免疫治疗剂
|
|
JP2018518483A
(ja)
|
2015-06-08 |
2018-07-12 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
|
|
EP3307265B1
(en)
|
2015-06-11 |
2023-12-13 |
Bionomics Limited |
Pharmaceutical combination and uses thereof
|
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
WO2016201425A1
(en)
|
2015-06-12 |
2016-12-15 |
Bristol-Myers Squibb Company |
Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
|
|
IL256245B
(en)
|
2015-06-16 |
2022-09-01 |
Merck Patent Gmbh |
Pd-l1 antagonist combination treatments
|
|
CN116327953A
(zh)
|
2015-06-17 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
|
BR112017027990A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Biotech, Inc. |
modulação imune e tratamento de tumores sólidos com anticorpos que se ligam especificamente ao cd38
|
|
UY36757A
(es)
|
2015-06-29 |
2016-12-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
|
|
ES2910035T3
(es)
|
2015-07-13 |
2022-05-11 |
Beyondspring Pharmaceuticals Inc |
Composiciones de plinabulina
|
|
WO2017011666A1
(en)
|
2015-07-14 |
2017-01-19 |
Bristol-Myers Squibb Company |
Method of treating cancer using immune checkpoint inhibitor
|
|
CA2991628C
(en)
|
2015-07-16 |
2020-04-07 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
WO2017019894A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
WO2017020291A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
US20180230431A1
(en)
|
2015-08-07 |
2018-08-16 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Therapy
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
EA039736B1
(ru)
*
|
2015-09-15 |
2022-03-04 |
Сайтомкс Терапьютикс, Инк. |
Анти-pdl1-антитела, активируемые анти-pdl1-антитела и способы их применения
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
WO2017055484A1
(en)
|
2015-09-29 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for determining the metabolic status of lymphomas
|
|
CA3000386A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
|
CN106565836B
(zh)
*
|
2015-10-10 |
2020-08-18 |
中国科学院广州生物医药与健康研究院 |
高亲和力的可溶性pdl-1分子
|
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
|
US10875923B2
(en)
|
2015-10-30 |
2020-12-29 |
Mayo Foundation For Medical Education And Research |
Antibodies to B7-H1
|
|
EA201891093A1
(ru)
|
2015-11-03 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела, специфически связывающие pd-1, и их применение
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
EP3378871A4
(en)
*
|
2015-11-17 |
2019-08-07 |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
PD-L1 ANTIBODY, ANTIGEN FRAGMENT FOR BINDING THEREOF AND PHARMACEUTICAL USE THEREOF
|
|
FI3377534T3
(fi)
|
2015-11-18 |
2025-08-22 |
Bristol Myers Squibb Co |
Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää
|
|
MX377351B
(es)
|
2015-11-19 |
2025-03-07 |
Genentech Inc |
Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico
|
|
KR20180082563A
(ko)
|
2015-11-19 |
2018-07-18 |
브리스톨-마이어스 스큅 컴퍼니 |
글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
|
|
JP2019505476A
(ja)
|
2015-12-01 |
2019-02-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
組合せ処置およびその方法
|
|
KR102809728B1
(ko)
|
2015-12-02 |
2025-05-21 |
주식회사 에스티큐브 |
글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법
|
|
WO2017093933A1
(en)
|
2015-12-03 |
2017-06-08 |
Glaxosmithkline Intellectual Property Development Limited |
Cyclic purine dinucleotides as modulators of sting
|
|
WO2017098421A1
(en)
|
2015-12-08 |
2017-06-15 |
Glaxosmithkline Intellectual Property Development Limited |
Benzothiadiazine compounds
|
|
JP7325186B2
(ja)
|
2015-12-09 |
2023-08-14 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
US20180364240A1
(en)
*
|
2015-12-10 |
2018-12-20 |
Medimmune, Llc |
Methods for treatment and selection of patients responsive to immune mediated cancer therapy
|
|
BR112018011781A2
(en)
|
2015-12-14 |
2018-12-04 |
Macrogenics, Inc. |
bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
|
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
|
HRP20231156T1
(hr)
|
2015-12-22 |
2024-01-05 |
Regeneron Pharmaceuticals, Inc. |
Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
ES2837155T3
(es)
|
2016-01-04 |
2021-06-29 |
Inst Nat Sante Rech Med |
Uso de PD-1 y Tim-3 como medida de células CD8+ para predecir y tratar el carcinoma de células renales
|
|
CN106939047B
(zh)
*
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
|
DK3402503T3
(da)
|
2016-01-13 |
2020-12-21 |
Acerta Pharma Bv |
Terapeutiske kombinationer af et antifolat og en btk-hæmmer
|
|
DK3405495T3
(da)
|
2016-01-21 |
2021-05-17 |
Innate Pharma |
Neutralisering af hæmmende veje i lymfocytter
|
|
ES2981745T3
(es)
|
2016-02-05 |
2024-10-10 |
Orionis Biosciences BV |
Agentes de señalización biespecíficos y usos de los mismos
|
|
IL260933B2
(en)
|
2016-02-08 |
2023-04-01 |
Beyondspring Pharmaceuticals Inc |
Preparations containing tocorsol or its analogues
|
|
US20210322415A1
(en)
|
2016-02-15 |
2021-10-21 |
Astrazeneca Ab |
Methods comprising fixed intermittent dosing of cediranib
|
|
AU2017224843A1
(en)
|
2016-02-25 |
2018-08-23 |
Cell Medica Switzerland Ag |
Binding members to PD-L1
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
CA3016313C
(en)
|
2016-03-01 |
2024-04-16 |
North Carolina State University |
Enhanced cancer immunotherapy by microneedle patch-assisted delivery
|
|
EP3309177B1
(en)
*
|
2016-03-04 |
2020-05-13 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof
|
|
SG10201913033UA
(en)
|
2016-03-04 |
2020-03-30 |
Bristol Myers Squibb Co |
Combination therapy with anti-cd73 antibodies
|
|
JP7270379B2
(ja)
|
2016-03-08 |
2023-05-10 |
イナート・ファルマ・ソシエテ・アノニム |
Ｓｉｇｌｅｃ中和抗体
|
|
WO2017153952A1
(en)
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
US11767362B1
(en)
|
2016-03-15 |
2023-09-26 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
|
US11110168B2
(en)
|
2016-03-15 |
2021-09-07 |
North Carolina State University |
Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent
|
|
WO2017161154A2
(en)
|
2016-03-16 |
2017-09-21 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Pd1 and pdl-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
|
|
AU2017234192B2
(en)
|
2016-03-16 |
2024-04-04 |
Amal Therapeutics Sa |
Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a TLR peptide agonist for use in medicine
|
|
JP7080213B2
(ja)
*
|
2016-03-23 |
2022-06-03 |
スーチョウ トランセンタ セラピューティクス カンパニー，リミテッド |
新規抗ｐｄ－ｌ１抗体
|
|
JP7572146B2
(ja)
|
2016-03-29 |
2024-10-23 |
エスティーキューブ アンド カンパニー，インコーポレイテッド |
グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法
|
|
JP7241541B2
(ja)
|
2016-03-29 |
2023-03-17 |
エスティーキューブ，インコーポレイテッド |
グリコシル化ｐｄ－ｌ１に特異的な二重機能抗体およびその使用方法
|
|
EP3436829A1
(en)
|
2016-03-30 |
2019-02-06 |
Centre Léon-Bérard |
Lymphocytes expressing cd73 in cancerous patient dictates therapy
|
|
WO2017176925A1
(en)
|
2016-04-05 |
2017-10-12 |
Bristol-Myers Squibb Company |
Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
|
|
PE20181884A1
(es)
|
2016-04-07 |
2018-12-07 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterociclicas utiles como moduladores de proteinas
|
|
WO2017176565A1
(en)
|
2016-04-07 |
2017-10-12 |
Eli Lilly And Company |
Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
|
|
ES2781474T3
(es)
|
2016-04-07 |
2020-09-02 |
Glaxosmithkline Ip Dev Ltd |
Amidas heterocíclicas útiles como moduladores de proteínas
|
|
JP7503887B2
(ja)
|
2016-04-15 |
2024-06-21 |
ジェネンテック， インコーポレイテッド |
がんを監視及び治療するための方法
|
|
AU2017248766A1
(en)
|
2016-04-15 |
2018-11-01 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
KR102414558B1
(ko)
|
2016-04-18 |
2022-06-29 |
셀덱스 쎄라퓨틱스, 인크. |
인간 cd40에 결합하는 효능성 항체 및 이의 용도
|
|
WO2017189433A1
(en)
*
|
2016-04-25 |
2017-11-02 |
Medimmune, Llc |
Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
|
|
KR20190003699A
(ko)
|
2016-05-05 |
2019-01-09 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
제스트 인핸서 상동체 2 억제제
|
|
AR108377A1
(es)
|
2016-05-06 |
2018-08-15 |
Medimmune Llc |
Proteínas de unión biespecíficas y sus usos
|
|
US11753463B2
(en)
|
2016-05-13 |
2023-09-12 |
Orionis Biosciences BV |
Therapeutic targeting of non-cellular structures
|
|
WO2017194783A1
(en)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Targeted mutant interferon-beta and uses thereof
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
JP7071288B2
(ja)
|
2016-05-18 |
2022-05-18 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
EP3458095A4
(en)
|
2016-05-18 |
2019-11-27 |
Albert Einstein College of Medicine |
VARIANT PD-L1 POLYPEPTIDE, T-CELL MODULATING MULTIPLE POLYPEPTIDE AND METHOD OF USE THEREOF
|
|
WO2017200969A1
(en)
|
2016-05-20 |
2017-11-23 |
Eli Lilly And Company |
Combination therapy with notch and pd-1 or pd-l1 inhibitors
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
WO2017205875A1
(en)
|
2016-05-27 |
2017-11-30 |
Dnatrix, Inc. |
Adenovirus and immunomodulator combination therapy
|
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
|
CN109475633A
(zh)
|
2016-06-02 |
2019-03-15 |
百时美施贵宝公司 |
在难治性霍奇金淋巴瘤中用纳武单抗阻断pd-1
|
|
AU2018276419A1
(en)
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
WO2017210473A1
(en)
|
2016-06-02 |
2017-12-07 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
|
|
KR20250107295A
(ko)
|
2016-06-03 |
2025-07-11 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
|
|
CN109476754A
(zh)
|
2016-06-03 |
2019-03-15 |
百时美施贵宝公司 |
抗-pd-1抗体在治疗结肠直肠癌患者中的用途
|
|
US20190292260A1
(en)
|
2016-06-03 |
2019-09-26 |
Bristol-Myers Squibb Company |
Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
|
|
KR20190015361A
(ko)
|
2016-06-06 |
2019-02-13 |
비욘드스프링 파마수티컬스, 인코포레이티드. |
호중구감소증을 줄이는 조성물 및 방법
|
|
CA3026982A1
(en)
|
2016-06-08 |
2017-12-14 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
CN109563034A
(zh)
|
2016-06-08 |
2019-04-02 |
葛兰素史密斯克莱知识产权发展有限公司 |
化学化合物
|
|
KR102434626B1
(ko)
*
|
2016-06-08 |
2022-08-24 |
애브비 인코포레이티드 |
항-b7-h3 항체 및 항체 약물 콘쥬게이트
|
|
CA3029813A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
JP7085708B2
(ja)
|
2016-06-20 |
2022-06-17 |
エフ－スター セラピューティクス リミテッド |
Ｌａｇ－３結合要素
|
|
KR102531889B1
(ko)
|
2016-06-20 |
2023-05-17 |
키맵 리미티드 |
항-pd-l1 및 il-2 사이토카인
|
|
KR20190028716A
(ko)
|
2016-06-29 |
2019-03-19 |
체크포인트 테라퓨틱스, 인크. |
Pd-l1-특이적 항체 및 이를 사용하는 방법
|
|
RU2656181C1
(ru)
*
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
CN117683135A
(zh)
|
2016-07-14 |
2024-03-12 |
百时美施贵宝公司 |
针对tim3的抗体及其用途
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
BR112019001136A2
(pt)
|
2016-07-20 |
2019-04-30 |
Glaxosmithkline Ip Dev Ltd |
compostos químicos
|
|
CN109715666B
(zh)
|
2016-07-20 |
2023-02-21 |
斯特库比股份有限公司 |
癌症治疗方法和使用结合糖基化pd-l1的抗体的组合的疗法
|
|
CN106243223B
(zh)
*
|
2016-07-28 |
2019-03-05 |
北京百特美博生物科技有限公司 |
抗人pdl1抗体及其用途
|
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
|
KR102604433B1
(ko)
|
2016-08-09 |
2023-11-24 |
키맵 리미티드 |
항-icos 항체
|
|
EP3496752B1
(en)
|
2016-08-12 |
2022-05-18 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor
|
|
US11312773B2
(en)
*
|
2016-08-15 |
2022-04-26 |
Fuso Pharmaceutical Industries, Ltd. |
Anti-PD-L1 antibody
|
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
|
|
EP3509634A1
(en)
|
2016-09-09 |
2019-07-17 |
TG Therapeutics Inc. |
Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
|
|
WO2018048975A1
(en)
|
2016-09-09 |
2018-03-15 |
Bristol-Myers Squibb Company |
Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
|
|
CN109789206A
(zh)
|
2016-09-16 |
2019-05-21 |
生态有限公司 |
抗体和检查点抑制剂的组合疗法
|
|
JP7346291B2
(ja)
|
2016-09-21 |
2023-09-19 |
アマル セラピューティクス エスエー |
癌を治療するための細胞透過性ペプチド、マルチエピトープ、及びｔｌｒペプチドアゴニストを含む融合体
|
|
WO2018055145A1
(en)
|
2016-09-26 |
2018-03-29 |
F. Hoffmann-La Roche Ag |
Predicting response to pd-1 axis inhibitors
|
|
CA3037008A1
(en)
|
2016-09-27 |
2018-04-05 |
Oncologie, Inc. |
Methods for treating cancer with bavituximab based on levels of .beta.2-glycoprotein 1, and assays therefor
|
|
WO2018064299A1
(en)
|
2016-09-29 |
2018-04-05 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
|
|
KR102804118B1
(ko)
|
2016-10-06 |
2025-05-09 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
MX2019003755A
(es)
|
2016-10-06 |
2019-08-12 |
Pfizer |
Regimen de dosificacion de avelumab para el tratamiento de cancer.
|
|
CN117801069A
(zh)
|
2016-10-07 |
2024-04-02 |
恩特罗姆公司 |
用于癌症疗法的免疫原性化合物
|
|
EP3522917A2
(en)
|
2016-10-07 |
2019-08-14 |
Enterome S.A. |
Microbiota sequence variants of tumor-related antigenic epitopes
|
|
CN117801066A
(zh)
|
2016-10-07 |
2024-04-02 |
恩特罗姆公司 |
用于癌症疗法的免疫原性化合物
|
|
AU2017343621B2
(en)
|
2016-10-11 |
2021-12-02 |
Agenus Inc. |
Anti-LAG-3 antibodies and methods of use thereof
|
|
RU2759728C2
(ru)
|
2016-10-11 |
2021-11-17 |
Ситлимик Инк. |
Лекарственное средство
|
|
WO2018077893A1
(en)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Targeted mutant interferon-gamma and uses thereof
|
|
EP3532504A1
(en)
|
2016-10-28 |
2019-09-04 |
Bristol-Myers Squibb Company |
Methods of treating urothelial carcinoma using an anti-pd-1 antibody
|
|
CN117088979A
(zh)
|
2016-10-30 |
2023-11-21 |
上海复宏汉霖生物技术股份有限公司 |
抗-pd-l1抗体及变异体
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
EP3535300B1
(en)
|
2016-11-03 |
2025-10-22 |
Bristol-Myers Squibb Company |
Activatable anti-ctla-4 antibodies and uses thereof
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
JP2020503260A
(ja)
|
2016-11-15 |
2020-01-30 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
WO2018098352A2
(en)
|
2016-11-22 |
2018-05-31 |
Jun Oishi |
Targeting kras induced immune checkpoint expression
|
|
JP7106563B2
(ja)
|
2016-11-29 |
2022-07-26 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
ナフトフラン誘導体、その調製、および使用方法
|
|
WO2018099539A1
(en)
|
2016-11-29 |
2018-06-07 |
Horst Lindhofer |
Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof
|
|
JP2020511407A
(ja)
|
2016-12-01 |
2020-04-16 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
併用療法
|
|
CA3045241A1
(en)
|
2016-12-01 |
2018-06-07 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
WO2018102786A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
|
CN118634323A
(zh)
|
2016-12-07 |
2024-09-13 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
AU2017373944B2
(en)
|
2016-12-07 |
2022-02-03 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
|
CN110366562A
(zh)
|
2016-12-12 |
2019-10-22 |
豪夫迈·罗氏有限公司 |
使用抗pd-l1抗体和抗雄激素治疗癌症的方法
|
|
JPWO2018110515A1
(ja)
|
2016-12-12 |
2019-10-24 |
第一三共株式会社 |
抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
|
|
WO2018111978A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
|
US10597438B2
(en)
|
2016-12-14 |
2020-03-24 |
Janssen Biotech, Inc. |
PD-L1 binding fibronectin type III domains
|
|
WO2018111973A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Cd8a-binding fibronectin type iii domains
|
|
WO2018112360A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating cancer
|
|
WO2018112364A1
(en)
|
2016-12-16 |
2018-06-21 |
Evelo Biosciences, Inc. |
Combination therapies for treating melanoma
|
|
US20190352363A1
(en)
|
2016-12-22 |
2019-11-21 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
|
|
EA039433B1
(ru)
|
2017-01-05 |
2022-01-27 |
Нетрис Фарма |
Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа
|
|
JP2020503363A
(ja)
|
2017-01-06 |
2020-01-30 |
ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド |
チューブリン結合化合物およびその治療的使用
|
|
EP3565560B1
(en)
|
2017-01-09 |
2024-05-29 |
OnkosXcel Therapeutics, LLC |
Predictive and diagnostic methods for prostate cancer
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
EP3565549B1
(en)
|
2017-01-09 |
2022-03-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
MX2019008346A
(es)
|
2017-01-13 |
2019-09-09 |
Agenus Inc |
Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
|
|
BR112019015069A2
(pt)
|
2017-01-24 |
2020-03-03 |
Pfizer Inc. |
Derivados de caliqueamicina e conjugados de anticorpo-fármaco dos mesmos
|
|
WO2018144764A1
(en)
|
2017-02-01 |
2018-08-09 |
Beyondspring Pharmaceuticals, Inc. |
Method of reducing neutropenia
|
|
US11384154B2
(en)
|
2017-02-06 |
2022-07-12 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
|
JP7586579B2
(ja)
|
2017-02-06 |
2024-11-19 |
オリオンズ バイオサイエンス インコーポレイテッド |
標的化改変型インターフェロン及びその使用
|
|
WO2018141959A1
(en)
|
2017-02-06 |
2018-08-09 |
Innate Pharma |
Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
|
|
EP3583127B1
(en)
|
2017-02-16 |
2024-11-20 |
Ying Zhang |
Anti-programmed death-ligand 1 (pd-l1) antibodies and therapeutic uses thereof
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
WO2018156494A1
(en)
|
2017-02-21 |
2018-08-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-pd-1 antibodies for treatment of lung cancer
|
|
CN108456251A
(zh)
*
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
|
JP7132232B2
(ja)
|
2017-02-24 |
2022-09-06 |
マクロジェニクス，インコーポレーテッド |
Ｃｄ１３７及び腫瘍抗原に結合できる二重特異性結合分子並びにその使用
|
|
WO2018154520A1
(en)
|
2017-02-27 |
2018-08-30 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors
|
|
JP7256127B2
(ja)
|
2017-03-01 |
2023-04-11 |
ジェネンテック， インコーポレイテッド |
がんのための診断及び治療方法
|
|
WO2018161872A1
(zh)
*
|
2017-03-06 |
2018-09-13 |
江苏恒瑞医药股份有限公司 |
抗b7-h3抗体、其抗原结合片段及其医药用途
|
|
EP4527854A3
(en)
*
|
2017-03-09 |
2025-06-25 |
Genmab A/S |
Antibodies against pd-l1
|
|
EP3596075B1
(en)
|
2017-03-15 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Azaindoles as inhibitors of hpk1
|
|
IL269000B2
(en)
|
2017-03-15 |
2024-06-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
BR112019018685A8
(pt)
|
2017-03-16 |
2023-03-21 |
Innate Pharma |
Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
|
|
EP3600427A1
(en)
|
2017-03-24 |
2020-02-05 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
MX2019011511A
(es)
|
2017-03-30 |
2019-11-18 |
Hoffmann La Roche |
Naftiridinas como inhibidores de cinasa 1 progenitora hematopoyetica (hpk1).
|
|
WO2018183964A1
(en)
|
2017-03-30 |
2018-10-04 |
Genentech, Inc. |
Isoquinolines as inhibitors of hpk1
|
|
AU2018241774B2
(en)
|
2017-03-30 |
2024-06-27 |
Merck Patent Gmbh |
Combination of an anti-PD-L1 antibody and a DNA-PK inhibitor for the treatment of cancer
|
|
EP3601355A1
(en)
|
2017-03-31 |
2020-02-05 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
EP3606960A1
(en)
|
2017-04-03 |
2020-02-12 |
Oncologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
MX2019012187A
(es)
|
2017-04-13 |
2019-11-25 |
Hoffmann La Roche |
Un inmunoconjugado de interleuquina-2, un agonista de cd40 y opcionalmente un antagonista de union al eje pd-1 para uso en metodos para tratar cancer.
|
|
KR20240017409A
(ko)
|
2017-04-13 |
2024-02-07 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
WO2018191660A1
(en)
|
2017-04-14 |
2018-10-18 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
RU2665790C1
(ru)
*
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
|
US12460208B2
(en)
|
2017-04-18 |
2025-11-04 |
Parr Biotechnology Co., Ltd. |
Immunomodulatory polynucleotides and uses thereof
|
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
|
EP3612201B1
(en)
|
2017-04-21 |
2023-10-25 |
Sillajen, Inc. |
Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
|
|
US11760777B2
(en)
|
2017-04-26 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
|
JP2020519621A
(ja)
|
2017-05-09 |
2020-07-02 |
テサロ， インコーポレイテッド |
癌を治療するための併用療法
|
|
CA3061791A1
(en)
|
2017-05-12 |
2019-10-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
Fusion protein containing tgf-.beta. receptor and medicinal uses thereof
|
|
MY195465A
(en)
*
|
2017-05-16 |
2023-01-25 |
Jiangsu Hengrui Medicine Co |
PD-L1 Antibody Pharmaceutical Composition and use Thereof
|
|
CN110869392A
(zh)
|
2017-05-16 |
2020-03-06 |
百时美施贵宝公司 |
用抗gitr激动性抗体治疗癌症
|
|
JP2020520923A
(ja)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル， インコーポレイテッド |
がんを処置するための方法
|
|
US11622961B2
(en)
|
2017-05-18 |
2023-04-11 |
Tesaro, Inc. |
Combination therapies for treating cancer
|
|
CN116333129A
(zh)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
包含经修饰的重链恒定区的抗体
|
|
WO2018219956A1
(en)
|
2017-05-29 |
2018-12-06 |
Gamamabs Pharma |
Cancer-associated immunosuppression inhibitor
|
|
AU2018275209A1
(en)
|
2017-05-30 |
2019-10-17 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
|
|
JP2020522691A
(ja)
|
2017-05-30 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｌａｇ−３陽性腫瘍の処置
|
|
EP3630842A2
(en)
|
2017-05-30 |
2020-04-08 |
Bristol-Myers Squibb Company |
Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
|
|
AU2018278327B2
(en)
|
2017-06-01 |
2023-03-16 |
Cytomx Therapeutics, Inc. |
Activatable anti-pdl1 antibodies and methods of use thereof
|
|
JP2020522508A
(ja)
|
2017-06-01 |
2020-07-30 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
抗ｐｄ−１抗体を用いる腫瘍の治療方法
|
|
WO2018225093A1
(en)
|
2017-06-07 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds as atf4 pathway inhibitors
|
|
CA3066048A1
(en)
|
2017-06-09 |
2018-12-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapy
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
WO2018234879A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
WO2018232725A1
(en)
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
|
WO2019003164A1
(en)
|
2017-06-27 |
2019-01-03 |
Neuracle Science Co., Ltd. |
USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
|
|
MX2019015738A
(es)
|
2017-06-27 |
2020-02-20 |
Novartis Ag |
Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
|
|
WO2019008507A1
(en)
|
2017-07-03 |
2019-01-10 |
Glaxosmithkline Intellectual Property Development Limited |
2- (4-CHLOROPHENOXY) -N - ((1- (2- (4-CHLOROPHENOXY) ETHYNAZETIDIN-3-YL) METHYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF ATF4 FOR THE TREATMENT OF CANCER AND D OTHER DISEASES
|
|
EP3649106A1
(en)
|
2017-07-03 |
2020-05-13 |
GlaxoSmithKline Intellectual Property Development Limited |
N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1]pentan-1-yl)-2-cyclobutane-1-carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
|
|
CN111263769B
(zh)
|
2017-07-10 |
2024-01-02 |
先天制药公司 |
Siglec-9中和性抗体
|
|
NZ761519A
(en)
|
2017-07-14 |
2023-07-28 |
Innate Tumor Immunity Inc |
Nlrp3 modulators
|
|
CN111163798A
(zh)
|
2017-07-20 |
2020-05-15 |
诺华股份有限公司 |
用于抗lag-3抗体的给药方案及其用途
|
|
US11674962B2
(en)
|
2017-07-21 |
2023-06-13 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2019021208A1
(en)
|
2017-07-27 |
2019-01-31 |
Glaxosmithkline Intellectual Property Development Limited |
USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
|
|
US11899017B2
(en)
|
2017-07-28 |
2024-02-13 |
Bristol-Myers Squibb Company |
Predictive peripheral blood biomarker for checkpoint inhibitors
|
|
KR102758346B1
(ko)
|
2017-08-04 |
2025-01-24 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
TW201912173A
(zh)
|
2017-08-07 |
2019-04-01 |
美商安進公司 |
三陰性乳癌或結腸直腸癌伴隨肝轉移之治療
|
|
CA3078605A1
(en)
|
2017-08-28 |
2019-03-07 |
Bristol-Myers Squibb Company |
Tim-3 antagonists for the treatment and diagnosis of cancers
|
|
KR20200052327A
(ko)
|
2017-09-04 |
2020-05-14 |
아게누스 인코포레이티드 |
혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
|
|
TW201922721A
(zh)
|
2017-09-07 |
2019-06-16 |
英商葛蘭素史克智慧財產發展有限公司 |
化學化合物
|
|
WO2019053617A1
(en)
|
2017-09-12 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
CHEMICAL COMPOUNDS
|
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
|
JP7382922B2
(ja)
|
2017-09-20 |
2023-11-17 |
中外製薬株式会社 |
Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
|
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
|
BR112020006286A2
(pt)
|
2017-09-30 |
2020-10-20 |
Tesaro, Inc. |
terapias de combinação para tratamento do câncer
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
JP2020536106A
(ja)
|
2017-10-05 |
2020-12-10 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
Ｈｉｖの処置に有用なインターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
|
|
US11377440B2
(en)
|
2017-10-05 |
2022-07-05 |
Glaxosmithkline Intellectual Property Development Limited |
Modulators of stimulator of interferon genes (STING)
|
|
MA50618A
(fr)
|
2017-10-06 |
2020-08-12 |
Tesaro Inc |
Polyrhérapies et leurs utilisations
|
|
JP7274469B2
(ja)
|
2017-10-06 |
2023-05-16 |
イナート・ファルマ・ソシエテ・アノニム |
Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
|
|
AU2018348432B2
(en)
|
2017-10-09 |
2025-08-28 |
Enterome S.A. |
Microbiota sequence variants of tumor-related antigenic epitopes
|
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
ANTI-LAP ANTIBODIES AND USES THEREOF
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
AU2018348431B2
(en)
|
2017-10-10 |
2025-10-02 |
Numab Therapeutics AG |
Antibodies targeting CD137 and methods of use thereof
|
|
MX2020003562A
(es)
|
2017-10-10 |
2020-10-01 |
Numab Therapeutics AG |
Anticuerpo multiespecifico.
|
|
CN120248120A
(zh)
*
|
2017-10-10 |
2025-07-04 |
努玛治疗有限公司 |
靶向pdl1的抗体及其使用方法
|
|
SG11202003081WA
(en)
|
2017-10-11 |
2020-05-28 |
Aurigene Discovery Tech Ltd |
Crystalline forms of 3-substituted 1,2,4-oxadiazole
|
|
EP3694545A4
(en)
|
2017-10-11 |
2021-12-01 |
Board Of Regents, The University Of Texas System |
HUMAN PD-L1 ANTIBODIES AND PROCEDURES FOR USE
|
|
JP2020536894A
(ja)
|
2017-10-15 |
2020-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
腫瘍処置法
|
|
SG11202003078VA
(en)
|
2017-10-18 |
2020-05-28 |
Alpine Immune Sciences Inc |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
|
AU2018353432A1
(en)
|
2017-10-19 |
2020-04-23 |
Debiopharm International S.A. |
Combination product for the treatment of cancer
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
EP3704159A1
(en)
|
2017-11-01 |
2020-09-09 |
Bristol-Myers Squibb Company |
Immunostimulatory agonistic antibodies for use in treating cancer
|
|
BR112020008537A2
(pt)
|
2017-11-03 |
2020-10-06 |
Aurigene Discovery Technologies Limited |
inibidores duplos de vias da tim-3 e da pd-1
|
|
AU2018359967A1
(en)
|
2017-11-06 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EA202090749A1
(ru)
|
2017-11-06 |
2020-08-19 |
Ориджен Дискавери Текнолоджис Лимитед |
Способы совместной терапии для иммуномодуляции
|
|
KR20200084880A
(ko)
|
2017-11-06 |
2020-07-13 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
WO2019094265A1
(en)
*
|
2017-11-10 |
2019-05-16 |
Armo Biosciences, Inc. |
Pd1 polypeptide binding molecules
|
|
AU2018369841A1
(en)
|
2017-11-14 |
2020-05-07 |
Pfizer Inc. |
EZH2 inhibitor combination therapies
|
|
SG11202005005YA
(en)
|
2017-11-30 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
WO2019122882A1
(en)
|
2017-12-19 |
2019-06-27 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
CN108144745B
(zh)
*
|
2017-12-20 |
2020-06-16 |
天康生物股份有限公司 |
一种分离装置以及减少布氏菌病活疫苗的内毒素含量的方法
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
EP3732198A1
(en)
|
2017-12-27 |
2020-11-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
|
US20210072244A1
(en)
|
2018-01-04 |
2021-03-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma resistant
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
CN111886241A
(zh)
|
2018-01-09 |
2020-11-03 |
库尔生物制药有限公司 |
多聚体t细胞调节多肽及其使用方法
|
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
CA3087105A1
(en)
*
|
2018-01-10 |
2019-07-18 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
|
|
BR112020013144A2
(pt)
|
2018-01-12 |
2020-12-08 |
Bristol-Myers Squibb Company |
Terapia de combinação com anticorpos anti-il-8 e anti-corpos anti-pd-1 para tratamento do câncer
|
|
US12129297B2
(en)
|
2018-01-12 |
2024-10-29 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
|
CN111868091A
(zh)
|
2018-01-16 |
2020-10-30 |
百时美施贵宝公司 |
用抗tim3抗体治疗癌症的方法
|
|
CA3088542A1
(en)
|
2018-01-22 |
2019-07-25 |
Bristol-Myers Squibb Company |
Compositions and methods of treating cancer
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
CA3096287A1
(en)
|
2018-01-22 |
2019-07-25 |
Pascal Biosciences Inc. |
Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
|
|
EP3743074A4
(en)
|
2018-01-24 |
2021-12-15 |
Beyondspring Pharmaceuticals Inc. |
COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
|
|
WO2019148089A1
(en)
|
2018-01-26 |
2019-08-01 |
Orionis Biosciences Inc. |
Xcr1 binding agents and uses thereof
|
|
CN111971059A
(zh)
|
2018-01-31 |
2020-11-20 |
细胞基因公司 |
使用过继细胞疗法和检查点抑制剂的组合疗法
|
|
AU2019215031B2
(en)
|
2018-01-31 |
2025-10-09 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
JP2021513361A
(ja)
|
2018-02-05 |
2021-05-27 |
オリオニス バイオサイエンシーズ，インコーポレイテッド |
線維芽細胞結合物質およびその使用
|
|
US20200405806A1
(en)
|
2018-02-08 |
2020-12-31 |
Bristol-Myers Squibb Company |
Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
|
|
US20200399383A1
(en)
|
2018-02-13 |
2020-12-24 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
WO2019162325A1
(en)
|
2018-02-21 |
2019-08-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
|
|
US12090142B2
(en)
|
2018-02-22 |
2024-09-17 |
Board Of Regents, The University Of Texas System |
Combination therapy for the treatment of cancer
|
|
US20200399376A1
(en)
|
2018-02-26 |
2020-12-24 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
SG11202008696RA
(en)
|
2018-03-12 |
2020-10-29 |
Inst Nat Sante Rech Med |
Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
|
|
AU2019233596A1
(en)
|
2018-03-14 |
2020-10-08 |
Merck Patent Gmbh |
Compounds and uses thereof to treat tumors in a subject
|
|
KR102874694B1
(ko)
|
2018-03-21 |
2025-10-23 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
CA3092695A1
(en)
|
2018-03-23 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Human pd-l2 antibodies and methods of use therefor
|
|
JP7351845B2
(ja)
|
2018-03-23 |
2023-09-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
|
|
AU2019239568B2
(en)
|
2018-03-23 |
2025-09-11 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use therefor
|
|
EP4501355A3
(en)
|
2018-03-23 |
2025-04-30 |
Board Of Regents, The University Of Texas System |
Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
|
|
AR115320A1
(es)
|
2018-03-30 |
2020-12-23 |
Merus Nv |
Anticuerpo multivalente
|
|
KR20200139724A
(ko)
|
2018-03-30 |
2020-12-14 |
브리스톨-마이어스 스큅 컴퍼니 |
종양을 치료하는 방법
|
|
EP3774903A1
(en)
|
2018-04-04 |
2021-02-17 |
Bristol-Myers Squibb Company |
Anti-cd27 antibodies and uses thereof
|
|
WO2019193541A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
|
|
WO2019193540A1
(en)
|
2018-04-06 |
2019-10-10 |
Glaxosmithkline Intellectual Property Development Limited |
Heteroaryl derivatives of formula (i) as atf4 inhibitors
|
|
US20210147570A1
(en)
|
2018-04-12 |
2021-05-20 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
US20210198374A1
(en)
|
2018-04-17 |
2021-07-01 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
|
SG11202010159RA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
BR112020021539A2
(pt)
|
2018-04-25 |
2021-01-19 |
Innate Tumor Immunity, Inc. |
Moduladores de nlrp3
|
|
WO2019206987A1
(en)
|
2018-04-25 |
2019-10-31 |
Medimmune Limited |
Formulations of human anti-pd-l1 antibodies
|
|
US20230182041A1
(en)
*
|
2018-04-25 |
2023-06-15 |
Medimmune, Llc |
Purification of antibodies
|
|
US11065317B2
(en)
|
2018-04-26 |
2021-07-20 |
Agenus Inc. |
Heat shock protein-binding peptide compositions and methods of use thereof
|
|
US20210246208A1
(en)
|
2018-05-04 |
2021-08-12 |
Merck Patent Gmbh |
Combined inhibition of pd-1/pd-l1, tgfb and dna-pk for the treatment of cancer
|
|
EP3788147A1
(en)
|
2018-05-04 |
2021-03-10 |
Tollys |
Tlr3 ligands that activate both epithelial and myeloid cells
|
|
US12209126B2
(en)
|
2018-05-15 |
2025-01-28 |
Medimmune Limited |
Treatment of cancer
|
|
GB201807924D0
(en)
|
2018-05-16 |
2018-06-27 |
Ctxt Pty Ltd |
Compounds
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CN112165974B
(zh)
|
2018-05-31 |
2024-11-08 |
诺华股份有限公司 |
乙型肝炎抗体
|
|
SG11202010579XA
(en)
|
2018-06-01 |
2020-12-30 |
Novartis Ag |
Binding molecules against bcma and uses thereof
|
|
WO2019241730A2
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
|
MX2020012107A
(es)
|
2018-06-18 |
2021-01-29 |
Innate Pharma |
Composiciones y procedimientos para el tratamiento del cancer.
|
|
CN112585166A
(zh)
|
2018-06-23 |
2021-03-30 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法
|
|
BR112021000332A2
(pt)
|
2018-07-09 |
2021-04-06 |
Glaxosmithkline Intellectual Property Development Limited |
Compostos químicos
|
|
MX2021000009A
(es)
|
2018-07-09 |
2021-03-09 |
Five Prime Therapeutics Inc |
Anticuerpos de union a transcripcion tipo inmunoglobulina 4 (ilt4).
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
CA3103385A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
|
WO2020014543A2
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
PE20210687A1
(es)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
Anticuerpos de union a vista a ph acido
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
EP3820569B1
(en)
|
2018-07-12 |
2024-11-20 |
invoX Pharma Limited |
Antibody molecules that bind pd-l1 and cd137
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
BR112021000282A2
(pt)
|
2018-07-12 |
2021-04-06 |
F-Star Beta Limited |
Moléculas de anticorpo que se ligam a cd137 e ox40
|
|
WO2020014583A1
(en)
|
2018-07-13 |
2020-01-16 |
Bristol-Myers Squibb Company |
Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
|
|
TWI822815B
(zh)
*
|
2018-07-14 |
2023-11-21 |
財團法人生物技術開發中心 |
抗-人類ｐｄ-ｌ１之抗體及其用途
|
|
CA3104147A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
|
WO2020018879A1
(en)
|
2018-07-20 |
2020-01-23 |
Surface Oncology, Inc. |
Anti-cd112r compositions and methods
|
|
CN112601584A
(zh)
|
2018-07-24 |
2021-04-02 |
豪夫迈·罗氏有限公司 |
异喹啉化合物及其用途
|
|
EP3826721B1
(en)
|
2018-07-24 |
2023-10-11 |
F. Hoffmann-La Roche AG |
Naphthyridine compounds and uses thereof
|
|
CA3107660A1
(en)
|
2018-07-26 |
2020-01-30 |
Bristol-Myers Squibb Company |
Lag-3 combination therapy for the treatment of cancer
|
|
WO2020031107A1
(en)
|
2018-08-08 |
2020-02-13 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical compounds
|
|
BR112021002642A2
(pt)
|
2018-08-16 |
2021-05-04 |
Innate Tumor Immunity, Inc. |
compostos de 4-amino-1h-imidazo[4,5-c]quinolina substituídos e métodos aprimorados para a preparação dos mesmos
|
|
EP3837015B1
(en)
|
2018-08-16 |
2024-02-14 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
WO2020037091A1
(en)
|
2018-08-16 |
2020-02-20 |
Innate Tumor Immunity, Inc. |
Imidazo[4,5-c]quinoline derived nlrp3-modulators
|
|
EP3841126A4
(en)
*
|
2018-08-20 |
2022-08-10 |
1Globe Biomedical Co., Ltd. |
NOVEL CANCER IMMUNOTHERAPY ANTIBODY COMPOSITIONS
|
|
AU2019328632A1
(en)
|
2018-08-27 |
2021-03-25 |
Pieris Pharmaceuticals Gmbh |
Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof
|
|
WO2020044206A1
(en)
|
2018-08-29 |
2020-03-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides as kinase inhibitors for use in the treatment cancer
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
|
|
JP7535500B2
(ja)
|
2018-09-03 |
2024-08-16 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体
|
|
WO2020048942A1
(en)
|
2018-09-04 |
2020-03-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
|
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
|
WO2020060771A1
(en)
*
|
2018-09-18 |
2020-03-26 |
Vanderbilt University |
Human monoclonal antibodies to staphylococcal aureus isd proteins and uses thereof
|
|
WO2020061377A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Spirocyclic 2,3-dihydro-7-azaindole compounds and uses thereof
|
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
US20220073638A1
(en)
|
2018-09-19 |
2022-03-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
US20220322655A1
(en)
|
2018-09-20 |
2022-10-13 |
Iovance Biotherapeutics, Inc. |
Expansion of TILs from Cryopreserved Tumor Samples
|
|
AU2019342133B8
(en)
|
2018-09-21 |
2025-08-07 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
JP2022502399A
(ja)
|
2018-09-26 |
2022-01-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
がんの治療のためのｐｄ−１アンタゴニスト、ａｔｒインヒビター、および白金製剤の組合せ
|
|
WO2020069402A1
(en)
|
2018-09-30 |
2020-04-02 |
Genentech, Inc. |
Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
|
|
US20220040183A1
(en)
|
2018-10-01 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of inhibitors of stress granule formation for targeting the regulation of immune responses
|
|
TW202024053A
(zh)
|
2018-10-02 |
2020-07-01 |
美商建南德克公司 |
異喹啉化合物及其用途
|
|
MA53822A
(fr)
|
2018-10-03 |
2021-08-11 |
Xencor Inc |
Protéines de fusion fc hétérodimères d'il -12
|
|
CN113166062A
(zh)
|
2018-10-03 |
2021-07-23 |
豪夫迈·罗氏有限公司 |
8-氨基异喹啉化合物及其用途
|
|
WO2020076799A1
(en)
|
2018-10-09 |
2020-04-16 |
Bristol-Myers Squibb Company |
Anti-mertk antibodies for treating cancer
|
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
|
MA53862A
(fr)
|
2018-10-12 |
2022-01-19 |
Xencor Inc |
Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
EP3867409A1
(en)
|
2018-10-16 |
2021-08-25 |
Novartis AG |
Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
|
|
WO2020081767A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
EP3867410A4
(en)
|
2018-10-18 |
2022-07-13 |
MedImmune, LLC |
METHODS OF DETERMINING A TREATMENT FOR CANCER PATIENTS
|
|
AU2019361124A1
(en)
|
2018-10-19 |
2021-06-03 |
Bristol-Myers Squibb Company |
Combination therapy for melanoma
|
|
CA3117746A1
(en)
|
2018-10-22 |
2020-04-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing
|
|
JP2022505647A
(ja)
|
2018-10-23 |
2022-01-14 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍の処置方法
|
|
KR20210084552A
(ko)
|
2018-10-29 |
2021-07-07 |
위스콘신 얼럼나이 리서어치 화운데이션 |
향상된 암 면역요법을 위한 면역관문 억제제와 복합체화된 덴드리틱 폴리머
|
|
US11564995B2
(en)
|
2018-10-29 |
2023-01-31 |
Wisconsin Alumni Research Foundation |
Peptide-nanoparticle conjugates
|
|
US12257286B2
(en)
|
2018-10-31 |
2025-03-25 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3873500A4
(en)
|
2018-10-31 |
2023-01-11 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
WO2020097350A1
(en)
|
2018-11-08 |
2020-05-14 |
Orionis Biosciences, Inc. |
Modulation of dendritic cell lineages
|
|
MX2021005018A
(es)
|
2018-11-09 |
2021-06-15 |
Jiangsu Hengrui Medicine Co |
Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
EP3880705A1
(en)
|
2018-11-14 |
2021-09-22 |
Bayer Aktiengesellschaft |
Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer
|
|
MX2021005708A
(es)
|
2018-11-16 |
2021-09-21 |
Bristol Myers Squibb Co |
Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
|
|
JP2022507495A
(ja)
|
2018-11-16 |
2022-01-18 |
アーキュール・インコーポレイテッド |
癌治療のための医薬の組合せ
|
|
EP3880231A1
(en)
|
2018-11-16 |
2021-09-22 |
NeoImmuneTech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
WO2020104479A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
|
|
EP3883964A1
(en)
|
2018-11-20 |
2021-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
|
EP3883610A4
(en)
|
2018-11-20 |
2022-11-02 |
Cornell University |
MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
|
|
US20220016079A1
(en)
|
2018-11-26 |
2022-01-20 |
Debiopharm International S.A. |
Combination treatment of hiv infections
|
|
US20220106400A1
(en)
|
2018-11-28 |
2022-04-07 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
|
EP3887823B1
(en)
|
2018-11-28 |
2024-01-17 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kit for assaying lytic potential of immune effector cells
|
|
US20220162705A1
(en)
|
2018-11-30 |
2022-05-26 |
Gbg Forschungs Gmbh |
Method for predicting the response to cancer immunotherapy in cancer patients
|
|
EP4342473A3
(en)
|
2018-11-30 |
2024-05-15 |
GlaxoSmithKline Intellectual Property Development Limited |
Compounds useful in hiv therapy
|
|
JP7584418B2
(ja)
|
2018-12-04 |
2024-11-15 |
ブリストル－マイヤーズ スクイブ カンパニー |
多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
|
|
KR20210099066A
(ko)
|
2018-12-04 |
2021-08-11 |
스미토모 다이니폰 파마 온콜로지, 인크. |
암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
|
|
WO2020117952A2
(en)
|
2018-12-05 |
2020-06-11 |
Genentech, Inc. |
Diagnostic methods and compositions for cancer immunotherapy
|
|
WO2020115261A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2020115262A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
|
WO2020120592A1
(en)
|
2018-12-12 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating melanoma
|
|
EP3897624A1
(en)
|
2018-12-17 |
2021-10-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of sulconazole as a furin inhibitor
|
|
US12221479B2
(en)
|
2018-12-19 |
2025-02-11 |
Bayer Aktiengesellschaft |
Pharmaceutical combination of anti CEACAM6 and TIM3 antibodies
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
WO2020127411A1
(en)
|
2018-12-19 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
|
|
US11618776B2
(en)
|
2018-12-20 |
2023-04-04 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
|
|
CN113271945A
(zh)
|
2018-12-20 |
2021-08-17 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
|
|
KR20210106531A
(ko)
|
2018-12-21 |
2021-08-30 |
에임 이뮤노테크 인코포레이티드 |
암 치료를 위한 조성물 및 방법
|
|
WO2020127885A1
(en)
|
2018-12-21 |
2020-06-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compositions for treating cancers and resistant cancers
|
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
|
JP7450622B2
(ja)
|
2018-12-21 |
2024-03-15 |
ヴァレリオ・セラピューティクス |
新規のコンジュゲートされた核酸分子及びその使用
|
|
JP2022514087A
(ja)
|
2018-12-21 |
2022-02-09 |
ノバルティス アーゲー |
ＩＬ－１β結合抗体の使用
|
|
WO2020128636A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
|
CA3122191A1
(en)
|
2018-12-26 |
2020-07-02 |
Innate Pharma |
Compounds and methods for treatment of head and neck cancer
|
|
MX2021007846A
(es)
*
|
2018-12-27 |
2021-10-26 |
Gigagen Inc |
Proteinas que se unen a anti-pd-l1 y metodos de uso de las mismas.
|
|
WO2020139956A1
(en)
|
2018-12-28 |
2020-07-02 |
Sparx Therapeutics Inc. |
Binding molecules specific for claudin 18.2, compositons and methods thereof, for treatment of cancer and other diseases
|
|
CN113453712A
(zh)
|
2018-12-28 |
2021-09-28 |
特兰斯吉恩股份有限公司 |
M2缺陷型痘病毒
|
|
JP7335341B2
(ja)
|
2019-01-14 |
2023-08-29 |
イネイト・テューマー・イミュニティ・インコーポレイテッド |
Ｎｌｒｐ３モジュレーター
|
|
KR102815870B1
(ko)
|
2019-01-14 |
2025-05-30 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제
|
|
CN115120716A
(zh)
|
2019-01-14 |
2022-09-30 |
健泰科生物技术公司 |
用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
|
|
ES2981835T3
(es)
|
2019-01-14 |
2024-10-10 |
Innate Tumor Immunity Inc |
Quinazolinas sustituidas como moduladores de NLRP3, para su uso en el tratamiento del cáncer
|
|
US12338228B2
(en)
|
2019-01-14 |
2025-06-24 |
Innate Tumor Immunity, Inc. |
NLRP3 modulators
|
|
JP7645185B2
(ja)
|
2019-01-15 |
2025-03-13 |
アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル |
変異したインターロイキン－３４（ｉｌ－３４）ポリペプチドおよび治療におけるその使用
|
|
JP7442536B2
(ja)
|
2019-01-30 |
2024-03-04 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンを患っている被験体が免疫チェックポイント阻害剤で反応を達成するかを特定するための方法及び組成物
|
|
AU2020214412A1
(en)
|
2019-02-01 |
2021-08-12 |
Glaxosmithkline Intellectual Property Development Limited |
Belantamab mafodotin in combination with pembrolizumab for treating cancer
|
|
US20220117911A1
(en)
|
2019-02-04 |
2022-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating blood-brain barrier
|
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
EP3924520A1
(en)
|
2019-02-13 |
2021-12-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
|
|
WO2020168244A1
(en)
|
2019-02-15 |
2020-08-20 |
Incelldx, Inc. |
Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
|
|
EA202192019A1
(ru)
|
2019-02-15 |
2021-11-02 |
Новартис Аг |
Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
|
|
JP7488826B2
(ja)
|
2019-02-15 |
2024-05-22 |
ノバルティス アーゲー |
置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
EP3927370B8
(en)
|
2019-02-19 |
2024-06-05 |
Turnstone Biologics Corp. |
Methods for producing autologous t cells useful to treat cancers and compositions thereof
|
|
BR112021016596A2
(pt)
*
|
2019-02-21 |
2021-12-21 |
Eucure Beijing Biopharma Co Ltd |
Anticorpo anti-pd-l1 e uso do mesmo
|
|
SG11202108450SA
(en)
|
2019-02-27 |
2021-09-29 |
Ionis Pharmaceuticals Inc |
Modulators of malat1 expression
|
|
UA128654C2
(uk)
|
2019-03-14 |
2024-09-18 |
Дженентек, Інк. |
Лікування раку біспецифічними антитілами до her2xcd3 у комбінації з моноклональним антитілом до her2
|
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
|
MX2021011289A
(es)
|
2019-03-22 |
2021-11-03 |
Sumitomo Pharma Oncology Inc |
Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
|
|
CN113677402A
(zh)
|
2019-03-28 |
2021-11-19 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
|
JP2022526960A
(ja)
|
2019-03-28 |
2022-05-27 |
ブリストル－マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
|
EP3948289A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Modulators of cell surface protein interactions and methods and compositions related to same
|
|
JP7760374B2
(ja)
|
2019-03-29 |
2025-10-27 |
ターンストーン バイオロジクス コーポレイション |
Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
|
|
CN119857140A
(zh)
|
2019-04-02 |
2025-04-22 |
免疫医疗有限责任公司 |
用于治疗肿瘤的抗-cd73、抗-pd-l1抗体和化疗
|
|
US20220177978A1
(en)
|
2019-04-02 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
CN113543809A
(zh)
|
2019-04-03 |
2021-10-22 |
塔尔格免疫治疗有限公司 |
用于治疗癌症的免疫疗法
|
|
WO2020208060A1
(en)
|
2019-04-09 |
2020-10-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
|
|
US20220185891A1
(en)
|
2019-04-12 |
2022-06-16 |
Vascular Biogenics Ltd. |
Methods of anti-tumor therapy
|
|
EP3956446A1
(en)
|
2019-04-17 |
2022-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
|
|
KR20220002967A
(ko)
|
2019-04-19 |
2022-01-07 |
제넨테크, 인크. |
항 mertk 항체 및 이의 사용 방법
|
|
SG11202111106WA
(en)
|
2019-04-23 |
2021-11-29 |
Innate Pharma |
Cd73 blocking antibodies
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
US20220220565A1
(en)
|
2019-04-30 |
2022-07-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
MX2021013222A
(es)
|
2019-05-03 |
2022-01-06 |
Genentech Inc |
Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
|
|
US20220211847A1
(en)
|
2019-05-06 |
2022-07-07 |
Medimmune Limited |
Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
|
|
CN114302875A
(zh)
|
2019-05-16 |
2022-04-08 |
斯汀塞拉股份有限公司 |
氧代吖啶基乙酸衍生物及使用方法
|
|
JP2022533194A
(ja)
|
2019-05-16 |
2022-07-21 |
スティングセラ インコーポレイテッド |
ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法
|
|
IL266728B
(en)
|
2019-05-19 |
2020-11-30 |
Yeda Res & Dev |
Identification of recurrent mutant neopeptides
|
|
EP3976090A1
(en)
|
2019-05-24 |
2022-04-06 |
Pfizer Inc. |
Combination therapies using cdk inhibitors
|
|
WO2020243568A1
(en)
|
2019-05-30 |
2020-12-03 |
Bristol-Myers Squibb Company |
Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
|
|
US20220233691A1
(en)
|
2019-05-30 |
2022-07-28 |
Bristol-Myers Squibb Company |
Cell localization signature and combination therapy
|
|
US20220363760A1
(en)
|
2019-05-30 |
2022-11-17 |
Bristol-Myers Squibb Company |
Multi-tumor gene signature for suitability to immuno-oncology therapy
|
|
CA3135988C
(en)
|
2019-06-10 |
2024-11-19 |
Shandong Boan Biotechnology Co Ltd |
Bifunctional fusion protein against PD-L1 and TGFS and its use
|
|
CA3143211A1
(en)
|
2019-06-26 |
2020-12-30 |
Glaxosmithkline Intellectual Property Development Limited |
Il1rap binding proteins
|
|
JP2022539208A
(ja)
|
2019-07-03 |
2022-09-07 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
|
|
US20220356255A1
(en)
|
2019-07-15 |
2022-11-10 |
Capella Bioscience Ltd |
Anti-pd-l1 antibodies
|
|
GB201910305D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
GB201910304D0
(en)
|
2019-07-18 |
2019-09-04 |
Ctxt Pty Ltd |
Compounds
|
|
EP4004548A1
(en)
|
2019-07-29 |
2022-06-01 |
Yeda Research and Development Co. Ltd |
Methods of treating and diagnosing lung cancer
|
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
CR20220076A
(es)
|
2019-08-30 |
2022-06-24 |
Agenus Inc |
Anticuerpos anti-cd96 y sus métodos de uso
|
|
CN114340673A
(zh)
|
2019-09-05 |
2022-04-12 |
阿斯利康(瑞典)有限公司 |
用于治疗广泛期小细胞肺癌（es-sclc）的组合物和方法
|
|
WO2021043961A1
(en)
|
2019-09-06 |
2021-03-11 |
Glaxosmithkline Intellectual Property Development Limited |
Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
|
|
WO2021048292A1
(en)
|
2019-09-11 |
2021-03-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
CN115947846A
(zh)
|
2019-09-12 |
2023-04-11 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
US12121565B2
(en)
|
2019-09-13 |
2024-10-22 |
Duke University |
Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
EP4031576A1
(en)
|
2019-09-18 |
2022-07-27 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
|
BR112022004831A2
(pt)
|
2019-09-19 |
2022-06-07 |
Bristol Myers Squibb Co |
Anticorpos que se ligam a vista em ph ácido
|
|
CN114555129A
(zh)
|
2019-09-20 |
2022-05-27 |
特兰斯吉恩股份有限公司 |
编码hpv多肽和il-2的痘病毒与抗pd-l1抗体的组合
|
|
KR20220066334A
(ko)
|
2019-09-22 |
2022-05-24 |
브리스톨-마이어스 스큅 컴퍼니 |
Lag-3 길항제 요법에 대한 정량적 공간 프로파일링
|
|
CA3152263A1
(en)
|
2019-09-25 |
2021-04-01 |
Julia SANTUCCI PEREIRA DEL BUONO |
Composite biomarker for cancer therapy
|
|
JP7280387B2
(ja)
|
2019-09-27 |
2023-05-23 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質
|
|
CN114555116A
(zh)
|
2019-09-27 |
2022-05-27 |
豪夫迈·罗氏有限公司 |
用于抗tigit和抗pd-l1拮抗剂抗体治疗的给药
|
|
JP2022550420A
(ja)
*
|
2019-09-30 |
2022-12-01 |
ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド |
抗ｐｄ－ｌ１抗原結合タンパク質及びその応用
|
|
EP4037693A1
(en)
|
2019-09-30 |
2022-08-10 |
Astrazeneca AB |
Combination treatment for cancer
|
|
EP3800201A1
(en)
|
2019-10-01 |
2021-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd28h stimulation enhances nk cell killing activities
|
|
CA3157024A1
(en)
|
2019-10-03 |
2021-04-08 |
Xencor, Inc. |
Targeted il-12 heterodimeric fc-fusion proteins
|
|
EP4037714A1
(en)
|
2019-10-03 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for modulating macrophages polarization
|
|
EP4037710A1
(en)
|
2019-10-04 |
2022-08-10 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
US12380963B2
(en)
|
2019-10-14 |
2025-08-05 |
The Medical College Of Wisconsin, Inc. |
Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy
|
|
CN114786682B
(zh)
|
2019-10-14 |
2024-07-16 |
Aro生物疗法公司 |
结合cd71的纤维粘连蛋白iii型结构域
|
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
|
WO2021074391A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing nasal intestinal type adenocarcinomas
|
|
CA3157665A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
|
KR20220103947A
(ko)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
베네토클락스 및 tim-3 억제제를 사용한 조합 요법
|
|
EP4049675A4
(en)
|
2019-10-25 |
2023-11-22 |
Daiichi Sankyo Company, Limited |
Combination of anti-garp antibody and immunoregulator
|
|
EP4051286A1
(en)
|
2019-10-29 |
2022-09-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating uveal melanoma
|
|
EP4055153A4
(en)
|
2019-11-04 |
2024-02-14 |
Duke University |
TREATMENT OF PRIMARY AND METASTASIC CANCER
|
|
CN114599372A
(zh)
|
2019-11-04 |
2022-06-07 |
阿斯利康(瑞典)有限公司 |
用于治疗癌症的组合疗法
|
|
CA3155922A1
(en)
|
2019-11-06 |
2021-05-14 |
Huang Huang |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
WO2021092221A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
WO2021092220A1
(en)
|
2019-11-06 |
2021-05-14 |
Bristol-Myers Squibb Company |
Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
|
|
EP4055609A1
(en)
|
2019-11-07 |
2022-09-14 |
Oncxerna Therapeutics, Inc. |
Classification of tumor microenvironments
|
|
WO2021092380A1
(en)
|
2019-11-08 |
2021-05-14 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for melanoma
|
|
EP4058593A4
(en)
|
2019-11-12 |
2023-11-15 |
Foundation Medicine, Inc. |
METHOD FOR DETECTING A FUSION GENE CODING A NEOANTIGEN
|
|
CA3155989A1
(en)
|
2019-11-13 |
2021-05-20 |
Jason Robert ZBIEG |
Therapeutic compounds and methods of use
|
|
EP4058465A1
(en)
|
2019-11-14 |
2022-09-21 |
Cohbar Inc. |
Cxcr4 antagonist peptides
|
|
US20230000864A1
(en)
|
2019-11-22 |
2023-01-05 |
Sumitomo Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
|
KR20220122639A
(ko)
|
2019-11-27 |
2022-09-02 |
미스트 쎄라퓨틱스, 엘엘씨 |
조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
|
|
TW202128155A
(zh)
|
2019-11-27 |
2021-08-01 |
日商賽多利克公司 |
醫藥組成物
|
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
|
CA3164751A1
(en)
|
2019-12-18 |
2021-06-24 |
Benjamin Joseph MORROW |
Compounds
|
|
US20230089255A1
(en)
|
2019-12-19 |
2023-03-23 |
Bristol-Myers Squibb Company |
Combinations of dgk inhibitors and checkpoint antagonists
|
|
WO2021123243A1
(en)
|
2019-12-19 |
2021-06-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions to treat cancers
|
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
CN115244052A
(zh)
|
2020-01-10 |
2022-10-25 |
先天肿瘤免疫公司 |
Nlrp3调节剂
|
|
AU2021207348A1
(en)
|
2020-01-17 |
2022-08-11 |
Novartis Ag |
Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
|
EP4090770A1
(en)
|
2020-01-17 |
2022-11-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating melanoma
|
|
EP4093772A1
(en)
*
|
2020-01-21 |
2022-11-30 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 antibodies
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
US20230067202A1
(en)
|
2020-01-28 |
2023-03-02 |
Glaxosmithkline Intellectual Property Development Limited |
Combination Treatments and Uses and Methods Thereof
|
|
AU2021214622A1
(en)
|
2020-01-29 |
2022-07-21 |
Merus N.V. |
Means and method for modulating immune cell engaging effects.
|
|
WO2021152548A1
(en)
|
2020-01-30 |
2021-08-05 |
Benitah Salvador Aznar |
Combination therapy for treatment of cancer and cancer metastasis
|
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
|
US20230072528A1
(en)
|
2020-02-05 |
2023-03-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
|
|
WO2021158938A1
(en)
|
2020-02-06 |
2021-08-12 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
|
CA3170133A1
(en)
|
2020-02-07 |
2021-08-12 |
AI Therapeutics, Inc. |
Anti-viral compositions and methods of use
|
|
EP4106813A4
(en)
|
2020-02-21 |
2024-03-27 |
MacroGenics, Inc. |
CD137 BINDING MOLECULES AND THEIR USES
|
|
KR20220164465A
(ko)
|
2020-02-26 |
2022-12-13 |
비르 바이오테크놀로지, 인코포레이티드 |
Sars-cov-2에 대한 항체 및 이의 사용 방법
|
|
EP4110799B1
(en)
|
2020-02-27 |
2024-11-06 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
CN116568341A
(zh)
|
2020-02-28 |
2023-08-08 |
百时美施贵宝公司 |
基于纤连蛋白的放射性标记的支架和抗体及其治疗诊断用途
|
|
US20230113705A1
(en)
|
2020-02-28 |
2023-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing, prognosing and managing treatment of breast cancer
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
KR20220151637A
(ko)
|
2020-03-06 |
2022-11-15 |
셀젠 콴티셀 리서치, 인크. |
Sclc 또는 sqnsclc를 치료하는데 사용하기 위한 lsd-1 억제제 및 니볼루맙의 조합
|
|
EP4114445A1
(en)
|
2020-03-06 |
2023-01-11 |
Ona Therapeutics S.L. |
Anti-cd36 antibodies and their use to treat cancer
|
|
JP2023516459A
(ja)
|
2020-03-09 |
2023-04-19 |
ブリストル－マイヤーズ スクイブ カンパニー |
増強されたアゴニスト活性を有するｃｄ４０に対する抗体
|
|
EP3878446A1
(en)
|
2020-03-09 |
2021-09-15 |
Universite De Geneve |
Hsd11b1 inhibitors for use in immunotherapy and uses thereof
|
|
PE20230821A1
(es)
|
2020-03-23 |
2023-05-19 |
Bristol Myers Squibb Co |
Anticuerpos anti-ccr8 para el tratamiento del cancer
|
|
UY39135A
(es)
|
2020-03-26 |
2021-10-29 |
Univ Vanderbilt |
ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
|
|
WO2021195485A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
|
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック， インコーポレイテッド |
がんに対する治療方法及び診断方法
|
|
WO2021205444A1
(en)
|
2020-04-06 |
2021-10-14 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing cancer and predicting responsiveness to therapy
|
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
|
AU2021256925A1
(en)
|
2020-04-14 |
2022-11-03 |
Ares Trading S.A. |
Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
|
|
US12159700B2
(en)
|
2020-04-22 |
2024-12-03 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
US12264190B2
(en)
|
2020-04-24 |
2025-04-01 |
Astrazeneca Ab |
Compositions and methods of treating cancer with chimeric antigen receptors
|
|
IL297701A
(en)
|
2020-04-27 |
2022-12-01 |
Twist Bioscience Corp |
Variable libraries of nucleic acids for the coronavirus
|
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
CN115485561A
(zh)
|
2020-05-05 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
预测对pd-1轴抑制剂的反应
|
|
TW202208395A
(zh)
|
2020-05-12 |
2022-03-01 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
CN115552036A
(zh)
|
2020-05-12 |
2022-12-30 |
阿斯利康(瑞典)有限公司 |
用于预测复发性/转移性头颈部鳞状细胞癌的总生存期的生物标志物
|
|
CN114729054A
(zh)
|
2020-05-12 |
2022-07-08 |
阿斯利康(瑞典)有限公司 |
使用免疫检查点抑制剂抗体治疗癌症的方法和组合
|
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
|
JP2023526400A
(ja)
|
2020-05-21 |
2023-06-21 |
アストラゼネカ・アクチエボラーグ |
局所進行性又は転移性尿路上皮がんにおける免疫療法に対する感受性に関連する遺伝子変異量
|
|
MX2022014943A
(es)
|
2020-05-26 |
2023-03-08 |
Inst Nat Sante Rech Med |
Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.
|
|
US20230279116A1
(en)
|
2020-06-03 |
2023-09-07 |
Mv Biotherapeutics Sa |
Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
|
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
TW202214857A
(zh)
|
2020-06-19 |
2022-04-16 |
法商昂席歐公司 |
新型結合核酸分子及其用途
|
|
IL298262A
(en)
|
2020-06-23 |
2023-01-01 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
WO2022003554A1
(en)
|
2020-07-01 |
2022-01-06 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
|
US20250262293A1
(en)
|
2020-07-07 |
2025-08-21 |
BioNTech SE |
Therapeutic rna for hpv-positive cancer
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
US20230266332A1
(en)
|
2020-07-28 |
2023-08-24 |
Inserm (Institut National De La Santè Et De La Recherch Médicale) |
Methods and compositions for preventing and treating a cancer
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
WO2022036079A1
(en)
|
2020-08-13 |
2022-02-17 |
Bristol-Myers Squibb Company |
Methods of redirecting of il-2 to target cells of interest
|
|
KR20230058442A
(ko)
|
2020-08-28 |
2023-05-03 |
브리스톨-마이어스 스큅 컴퍼니 |
간세포성 암종에 대한 lag-3 길항제 요법
|
|
CN116438199A
(zh)
|
2020-08-31 |
2023-07-14 |
百时美施贵宝公司 |
细胞定位特征和免疫疗法
|
|
CN114106190B
(zh)
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
BR112023001864A2
(pt)
|
2020-09-14 |
2023-03-28 |
Boehringer Ingelheim Int |
Vacina de reforço primário heteróloga
|
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
|
US20230364127A1
(en)
|
2020-10-06 |
2023-11-16 |
Codiak Biosciences, Inc. |
Extracellular vesicle-aso constructs targeting stat6
|
|
AU2021357354A1
(en)
|
2020-10-08 |
2023-04-20 |
Targimmune Therapeutics Ag |
Immunotherapy for the treatment of cancer
|
|
IL301760A
(en)
|
2020-10-12 |
2023-05-01 |
Astrazeneca Ab |
ADJUVANT DURVALUMAB in combination with chemotherapy for the treatment of cancer
|
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
|
WO2022084531A1
(en)
|
2020-10-23 |
2022-04-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating glioma
|
|
WO2022087402A1
(en)
|
2020-10-23 |
2022-04-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
US20240148740A1
(en)
|
2020-10-28 |
2024-05-09 |
Ikena Oncology, Inc. |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20240010739A1
(en)
|
2020-11-12 |
2024-01-11 |
Institut National De La Santé Et De La Recherche Médicale (Inserm) |
Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
|
|
CA3201519A1
(en)
|
2020-11-13 |
2022-05-19 |
Genentech, Inc. |
Methods and compositions comprising a krasg12c inhibitor and a pd-l1 binding antagonist for treating lung cancer
|
|
EP4244391A1
(en)
|
2020-11-16 |
2023-09-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
WO2022101463A1
(en)
|
2020-11-16 |
2022-05-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
|
|
EP4244392A1
(en)
|
2020-11-16 |
2023-09-20 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for predicting and treating uveal melanoma
|
|
MX2023006488A
(es)
|
2020-12-02 |
2023-06-20 |
Genentech Inc |
Procedimientos y composiciones para el tratamiento neoadyuvante y adyuvante del carcinoma urotelial.
|
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
US12180284B2
(en)
|
2020-12-16 |
2024-12-31 |
Molecular Templates, Inc. |
Clinical methods for use of a PD-L1-binding molecule comprising a Shiga toxin effector
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性ｒｎａ
|
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
|
EP4267105B1
(en)
|
2020-12-28 |
2025-03-26 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
JP2024501029A
(ja)
|
2020-12-28 |
2024-01-10 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与
|
|
CN116744971A
(zh)
*
|
2021-01-04 |
2023-09-12 |
上海翰森生物医药科技有限公司 |
一种抗erbb3受体的抗体或其抗原结合片段及其医药用途
|
|
WO2022148736A1
(en)
|
2021-01-05 |
2022-07-14 |
Transgene |
Vectorization of muc1 t cell engager
|
|
CA3206549A1
(en)
|
2021-01-29 |
2022-08-04 |
Frederick G. Vogt |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
CN117222413A
(zh)
|
2021-02-10 |
2023-12-12 |
同润生物医药(上海)有限公司 |
治疗肿瘤的方法和组合
|
|
CA3209869A1
(en)
*
|
2021-02-26 |
2022-09-01 |
Fred Hutchinson Cancer Center |
Protective antibodies against respiratory viral infections
|
|
IL305427A
(en)
|
2021-03-02 |
2023-10-01 |
Glaxosmithkline Ip Dev Ltd |
Substituted pyridines as DNMT1 inhibitors
|
|
EP4308118A1
(en)
|
2021-03-17 |
2024-01-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and compositions for treating melanoma
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
|
WO2022204438A1
(en)
|
2021-03-25 |
2022-09-29 |
Oncxerna Therapeutics, Inc. |
Targeted therapies in cancer
|
|
MX2023011332A
(es)
|
2021-03-26 |
2023-10-03 |
Astrazeneca Ab |
Tratamientos combinados para el melanoma.
|
|
JP2024514245A
(ja)
|
2021-03-29 |
2024-03-29 |
ジュノー セラピューティクス インコーポレイテッド |
チェックポイント阻害剤療法とｃａｒ ｔ細胞療法との組合せを用いた投薬および処置のための方法
|
|
JP2024511831A
(ja)
|
2021-03-31 |
2024-03-15 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
抗原結合タンパク質およびそれらの組み合わせ
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型ｃｄｃｐ１に対する抗体およびその使用
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022217123A2
(en)
|
2021-04-08 |
2022-10-13 |
Nurix Therapeutics, Inc. |
Combination therapies with cbl-b inhibitor compounds
|
|
CA3215047A1
(en)
|
2021-04-09 |
2022-10-13 |
Lan Huang |
Therapeutic compositions and methods for treating tumors
|
|
KR20230167097A
(ko)
|
2021-04-09 |
2023-12-07 |
제넨테크, 인크. |
Raf 억제제와 pd-1 축 억제제를 사용한 병용 요법
|
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
|
WO2022214653A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
New scaffold for bifunctional molecules with improved properties
|
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
|
WO2022219080A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve nk cells cytotoxicity
|
|
BR112023021318A2
(pt)
|
2021-04-14 |
2023-12-19 |
Aro Biotherapeutics Company |
Conjugados de domínio fn3-sirna e usos dos mesmos
|
|
AU2022258566A1
(en)
|
2021-04-14 |
2023-10-12 |
Aro Biotherapeutics Company |
Cd71 binding fibronectin type iii domains
|
|
US20240158861A1
(en)
|
2021-04-23 |
2024-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating cell senescence accumulation related disease
|
|
WO2022226539A1
(en)
*
|
2021-04-23 |
2022-10-27 |
Immunome, Inc. |
Methods of administering antibodies against sars-cov-2 spike protein
|
|
WO2022229966A1
(en)
|
2021-04-29 |
2022-11-03 |
Yeda Research And Development Co. Ltd. |
T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
|
|
EP4330436A1
(en)
|
2021-04-30 |
2024-03-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods and compositions for cancer
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
US20220396623A1
(en)
|
2021-05-18 |
2022-12-15 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
AU2022277263A1
(en)
|
2021-05-21 |
2023-12-14 |
Tianjin Lipogen Technology Co., Ltd |
Pharmaceutical combination and use thereof
|
|
WO2022248478A1
(en)
|
2021-05-24 |
2022-12-01 |
Astrazeneca Ab |
Compositions and methods for treating lung cancer
|
|
WO2022251853A1
(en)
|
2021-05-25 |
2022-12-01 |
Edelweiss Immune Inc |
C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
|
|
MX2023014084A
(es)
|
2021-05-26 |
2024-02-27 |
Ct Inmunologia Molecular |
Uso de composiciones terapeuticas para el tratamiento de pacientes con tumores de origen epitelial.
|
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
|
US20240316104A1
(en)
|
2021-06-29 |
2024-09-26 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
IL309071A
(en)
|
2021-07-02 |
2024-02-01 |
Genentech Inc |
Methods and compositions for the treatment of cancer
|
|
KR20240043747A
(ko)
|
2021-07-02 |
2024-04-03 |
예일 유니버시티 |
암을 치료하기 위한 조성물 및 방법
|
|
US20240316005A1
(en)
|
2021-07-05 |
2024-09-26 |
Institut National de la Santé et de la Recherche Médicale |
Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
|
|
US20240327544A1
(en)
|
2021-07-13 |
2024-10-03 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
|
TW202320848A
(zh)
|
2021-07-28 |
2023-06-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
|
CN117715936A
(zh)
|
2021-07-28 |
2024-03-15 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的方法和组合物
|
|
MX2024001415A
(es)
|
2021-07-30 |
2024-02-27 |
Ona Therapeutics S L |
Anticuerpos anti-cd36 y su uso para tratar el cancer.
|
|
US20250127917A1
(en)
|
2021-08-31 |
2025-04-24 |
Yale University |
Compositions and methods for treating cancers
|
|
JP2024534186A
(ja)
|
2021-09-02 |
2024-09-18 |
ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ |
副作用が低減された抗ｃｅｃａｍ６抗体
|
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
TW202327595A
(zh)
|
2021-10-05 |
2023-07-16 |
美商輝瑞大藥廠 |
用於治療癌症之氮雜內醯胺化合物的組合
|
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
|
EP4410842A4
(en)
|
2021-10-21 |
2025-08-27 |
Adlai Nortye Biopharma Co Ltd |
FUSION POLYPEPTIDE AND ITS USE
|
|
KR20240099331A
(ko)
|
2021-10-28 |
2024-06-28 |
라이엘 이뮤노파마, 인크. |
면역 세포를 배양하기 위한 방법
|
|
CN118176214A
(zh)
|
2021-10-29 |
2024-06-11 |
百时美施贵宝公司 |
血液癌症的lag-3拮抗剂疗法
|
|
WO2023078900A1
(en)
|
2021-11-03 |
2023-05-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and compositions for treating triple negative breast cancer (tnbc)
|
|
WO2023079428A1
(en)
|
2021-11-03 |
2023-05-11 |
Pfizer Inc. |
Combination therapies using tlr7/8 agonist
|
|
WO2023080900A1
(en)
|
2021-11-05 |
2023-05-11 |
Genentech, Inc. |
Methods and compositions for classifying and treating kidney cancer
|
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
|
CN118765283A
(zh)
|
2021-11-17 |
2024-10-11 |
国家健康科学研究所 |
通用沙贝病毒疫苗
|
|
EP4436957A1
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
JP2024543912A
(ja)
|
2021-11-24 |
2024-11-26 |
ジェネンテック， インコーポレイテッド |
二環式治療用化合物及びがんの処置における使用方法
|
|
WO2023111203A1
(en)
|
2021-12-16 |
2023-06-22 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
|
US20250041261A1
(en)
|
2021-12-21 |
2025-02-06 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating melanoma
|
|
WO2023129438A1
(en)
|
2021-12-28 |
2023-07-06 |
Wisconsin Alumni Research Foundation |
Hydrogel compositions for use for depletion of tumor associated macrophages
|
|
WO2023137161A1
(en)
|
2022-01-14 |
2023-07-20 |
Amgen Inc. |
Triple blockade of tigit, cd112r, and pd-l1
|
|
CN118765285A
(zh)
|
2022-01-26 |
2024-10-11 |
百时美施贵宝公司 |
用于肝细胞癌的组合疗法
|
|
US20250099588A1
(en)
|
2022-01-28 |
2025-03-27 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
WO2023154799A1
(en)
|
2022-02-14 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination immunotherapy for treating cancer
|
|
US20250179174A1
(en)
|
2022-02-25 |
2025-06-05 |
Bristol-Myers Squibb Company |
Combination therapy for colorectal carcinoma
|
|
CN119855831A
(zh)
|
2022-03-03 |
2025-04-18 |
辉瑞大药厂 |
与il-4、il-13和/或tslp结合的多特异性抗体及其用途
|
|
WO2023168404A1
(en)
|
2022-03-04 |
2023-09-07 |
Bristol-Myers Squibb Company |
Methods of treating a tumor
|
|
US20250216391A1
(en)
|
2022-03-07 |
2025-07-03 |
Astrazeneca Ab |
Method for predicting patient response to immunotherapy
|
|
CN119156403A
(zh)
|
2022-03-08 |
2024-12-17 |
阿伦蒂斯治疗股份公司 |
抗紧密连接蛋白-1抗体增加t细胞可用性的用途
|
|
EP4493189A1
(en)
|
2022-03-14 |
2025-01-22 |
Laekna Limited |
Combination treatment for cancer
|
|
CN119031932A
(zh)
|
2022-03-16 |
2024-11-26 |
第一三共株式会社 |
多特异性分子和免疫检查点抑制剂的组合
|
|
CN119072332A
(zh)
|
2022-03-18 |
2024-12-03 |
阿斯利康(瑞典)有限公司 |
使用抗pd-l1抗体与化学疗法的组合治疗胆道癌的方法
|
|
US20250206775A1
(en)
|
2022-03-18 |
2025-06-26 |
Bristol-Myers Squibb Company |
Methods of isolating polypeptides
|
|
WO2023192478A1
(en)
|
2022-04-01 |
2023-10-05 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
|
EP4504780A1
(en)
|
2022-04-01 |
2025-02-12 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023196987A1
(en)
|
2022-04-07 |
2023-10-12 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
|
CN119731651A
(zh)
|
2022-04-08 |
2025-03-28 |
百时美施贵宝公司 |
三级淋巴结构的机器学习标识、分类和量化
|
|
CN119384432A
(zh)
|
2022-04-13 |
2025-01-28 |
基因泰克公司 |
治疗性蛋白质的药物组合物和使用方法
|
|
KR20250004727A
(ko)
|
2022-04-13 |
2025-01-08 |
제넨테크, 인크. |
모수네투주맙의 약학적 조성물 및 사용 방법
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
JP2025517650A
(ja)
|
2022-05-11 |
2025-06-10 |
ジェネンテック， インコーポレイテッド |
抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
|
|
AR129314A1
(es)
|
2022-05-12 |
2024-08-14 |
Genentech Inc |
Procedimientos y composiciones que comprenden un inhibidor de shp2 y un antagonista de unión a pd-l1
|
|
EP4525991A1
(en)
|
2022-05-18 |
2025-03-26 |
Kymab Limited |
Uses of anti-icos antibodies
|
|
JP2025517908A
(ja)
|
2022-05-24 |
2025-06-12 |
第一三共株式会社 |
抗ｃｄｈ６抗体－薬物コンジュゲートの投薬量レジメン
|
|
AR129423A1
(es)
|
2022-05-27 |
2024-08-21 |
Viiv Healthcare Co |
Compuestos útiles en la terapia contra el hiv
|
|
WO2023235415A1
(en)
|
2022-06-01 |
2023-12-07 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
|
|
EP4531916A1
(en)
|
2022-06-02 |
2025-04-09 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
WO2024003241A1
(en)
|
2022-06-30 |
2024-01-04 |
Astrazeneca Ab |
Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4
|
|
TW202417042A
(zh)
|
2022-07-13 |
2024-05-01 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
IL318252A
(en)
|
2022-07-19 |
2025-03-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
WO2024023740A1
(en)
|
2022-07-27 |
2024-02-01 |
Astrazeneca Ab |
Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
|
|
US20250360222A1
(en)
|
2022-07-28 |
2025-11-27 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
|
JP2025528280A
(ja)
*
|
2022-08-05 |
2025-08-26 |
エイチビーエム・アルファ・セラピューティクス・インコーポレイテッド |
抗コルチコトロピン放出ホルモン抗体および多嚢胞性卵巣症候群
|
|
WO2024033400A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sk2 inhibitor for the treatment of pancreatic cancer
|
|
WO2024033399A1
(en)
|
2022-08-10 |
2024-02-15 |
Institut National de la Santé et de la Recherche Médicale |
Sigmar1 ligand for the treatment of pancreatic cancer
|
|
WO2024040175A1
(en)
|
2022-08-18 |
2024-02-22 |
Pulmatrix Operating Company, Inc. |
Methods for treating cancer using inhaled angiogenesis inhibitor
|
|
CN120153254A
(zh)
|
2022-09-01 |
2025-06-13 |
基因泰克公司 |
膀胱癌的治疗和诊断方法
|
|
WO2024052356A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
|
|
WO2024054992A1
(en)
|
2022-09-09 |
2024-03-14 |
Bristol-Myers Squibb Company |
Methods of separating chelator
|
|
TW202428254A
(zh)
|
2022-09-09 |
2024-07-16 |
瑞典商阿斯特捷利康公司 |
用於治療晚期實性瘤之組成物及方法
|
|
WO2024056716A1
(en)
|
2022-09-14 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
|
|
JP2025533015A
(ja)
|
2022-09-30 |
2025-10-03 |
アレンティス セラピューティクス アクチェンゲゼルシャフト |
薬物抵抗性肝細胞癌の処置
|
|
EP4599088A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating lung cancer
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
EP4599089A1
(en)
|
2022-10-05 |
2025-08-13 |
Genentech, Inc. |
Methods and compositions for classifying and treating bladder cancer
|
|
JP7730432B2
(ja)
|
2022-10-19 |
2025-08-27 |
アステラス製薬株式会社 |
がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用
|
|
EP4605000A1
(en)
|
2022-10-21 |
2025-08-27 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of osteoarthritis
|
|
AU2023369055A1
(en)
|
2022-10-24 |
2025-05-15 |
Cancer Research Technology Limited |
Tumour sensitisation to checkpoint inhibitors with redox status modifier
|
|
EP4608995A1
(en)
|
2022-10-24 |
2025-09-03 |
Memorial Sloan-Kettering Cancer Center |
Tumour stratification for responsiveness to an immune checkpoint inhibitor
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
WO2024094688A1
(en)
|
2022-11-01 |
2024-05-10 |
Heidelberg Pharma Research Gmbh |
Anti-gucy2c antibody and uses thereof
|
|
WO2024097328A1
(en)
|
2022-11-03 |
2024-05-10 |
Incyte Corporation |
Combination therapies comprising an anti-gitr antibody for treating cancers
|
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024114605A1
(zh)
|
2022-11-29 |
2024-06-06 |
杭州阿诺生物医药科技有限公司 |
一种融合多肽及其用途
|
|
AU2023403103A1
(en)
|
2022-12-01 |
2025-07-10 |
Medimmune Limited |
Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
|
|
CN120225561A
(zh)
|
2022-12-01 |
2025-06-27 |
先天制药公司 |
用于癌症新辅助治疗的包含抗cd39抗体的组合物和方法
|
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
|
AU2023393653A1
(en)
|
2022-12-14 |
2025-05-22 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
|
KR20250122520A
(ko)
|
2022-12-20 |
2025-08-13 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신을 이용한 췌장암 치료 방법
|
|
IL321575A
(en)
|
2022-12-21 |
2025-08-01 |
Bristol Myers Squibb Co |
Combination therapy for lung cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
WO2024150177A1
(en)
|
2023-01-11 |
2024-07-18 |
Advesya |
Treatment methods for solid tumors
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
EP4649173A1
(en)
|
2023-01-13 |
2025-11-19 |
Akrivia Biomedics Limited |
Method of profiling diseases
|
|
WO2024160721A1
(en)
|
2023-01-30 |
2024-08-08 |
Kymab Limited |
Antibodies
|
|
WO2024163477A1
(en)
|
2023-01-31 |
2024-08-08 |
University Of Rochester |
Immune checkpoint blockade therapy for treating staphylococcus aureus infections
|
|
WO2024192051A1
(en)
|
2023-03-13 |
2024-09-19 |
Turnstone Biologics Corp. |
Composition of selected tumor infiltrating lymphocytes and related methods of producing and using the same
|
|
WO2024196952A1
(en)
|
2023-03-20 |
2024-09-26 |
Bristol-Myers Squibb Company |
Tumor subtype assessment for cancer therapy
|
|
WO2024200571A1
(en)
|
2023-03-28 |
2024-10-03 |
Institut National de la Santé et de la Recherche Médicale |
Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
|
|
WO2024216028A1
(en)
|
2023-04-12 |
2024-10-17 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
CN120936347A
(zh)
|
2023-04-14 |
2025-11-11 |
阿斯利康(瑞典)有限公司 |
非小细胞肺癌的治疗
|
|
WO2024213767A1
(en)
|
2023-04-14 |
2024-10-17 |
Institut National de la Santé et de la Recherche Médicale |
Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
|
|
WO2024228167A1
(en)
|
2023-05-03 |
2024-11-07 |
Iox Therapeutics Inc. |
Inkt cell modulator liposomal compositions and methods of use
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024233646A1
(en)
|
2023-05-10 |
2024-11-14 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
|
WO2024231384A1
(en)
|
2023-05-10 |
2024-11-14 |
Institut National de la Santé et de la Recherche Médicale |
Compositions for treating senescence related disease
|
|
TW202509074A
(zh)
|
2023-05-17 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
用於治療子宮頸癌之方法及組合
|
|
WO2024245951A1
(en)
|
2023-05-26 |
2024-12-05 |
Institut National de la Santé et de la Recherche Médicale |
Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
|
|
CN119055777A
(zh)
|
2023-05-31 |
2024-12-03 |
阿斯利康(瑞典)有限公司 |
用于治疗卵巢癌的方法、组合物和组合
|
|
WO2024256635A1
(en)
|
2023-06-15 |
2024-12-19 |
Institut National de la Santé et de la Recherche Médicale |
Dpm1 inhibitor for treating cancer
|
|
WO2024261302A1
(en)
|
2023-06-22 |
2024-12-26 |
Institut National de la Santé et de la Recherche Médicale |
Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
|
|
WO2024263904A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024263195A1
(en)
|
2023-06-23 |
2024-12-26 |
Genentech, Inc. |
Methods for treatment of liver cancer
|
|
WO2024261239A1
(en)
|
2023-06-23 |
2024-12-26 |
Imcheck Therapeutics |
Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
|
|
WO2025003193A1
(en)
|
2023-06-26 |
2025-01-02 |
Institut National de la Santé et de la Recherche Médicale |
Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
|
|
WO2025006811A1
(en)
|
2023-06-27 |
2025-01-02 |
Lyell Immunopharma, Inc. |
Methods for culturing immune cells
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025024257A1
(en)
|
2023-07-21 |
2025-01-30 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
IL304887A
(en)
|
2023-07-31 |
2025-02-01 |
Yeda Res & Dev |
T-cell receptor directed against RAS neoantigen
|
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
|
CN119488588A
(zh)
|
2023-08-17 |
2025-02-21 |
阿斯利康(瑞典)有限公司 |
用于治疗子宫内膜癌的方法、组合物和组合
|
|
WO2025049277A1
(en)
|
2023-08-25 |
2025-03-06 |
Genentech, Inc. |
Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
TW202529802A
(zh)
|
2023-09-22 |
2025-08-01 |
瑞典商阿斯特捷利康公司 |
胃癌和／或胃食管結合部癌的治療
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
WO2025080865A1
(en)
|
2023-10-11 |
2025-04-17 |
Turnstone Biologics Corp. |
Combination of tumor infiltrating lymphocytes (til) and low dose radiation
|
|
WO2025078632A1
(en)
|
2023-10-12 |
2025-04-17 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from cancer
|
|
WO2025085404A1
(en)
|
2023-10-16 |
2025-04-24 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treating lung cancer
|
|
WO2025083600A1
(en)
|
2023-10-17 |
2025-04-24 |
Astrazeneca Ab |
Predicting response to neoadjuvant treatment in non-small cell lung cancer
|
|
WO2025085781A1
(en)
|
2023-10-19 |
2025-04-24 |
Genentech, Inc. |
Combinations of il15/il15r alpha heterodimeric fc-fusion proteins and her2xcd3 bispecific antibodies for the treatment of her2-positive cancers
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025109597A1
(en)
|
2023-11-22 |
2025-05-30 |
Yeda Research And Development Co. Ltd. |
T cell receptors directed against androgen receptor mutation
|
|
WO2025120866A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025121445A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
|
|
WO2025120867A1
(en)
|
2023-12-08 |
2025-06-12 |
Astellas Pharma Inc. |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
|
|
WO2025132479A1
(en)
|
2023-12-18 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Flt3 inhibitor for modulating macrophages polarization
|
|
WO2025132770A1
(en)
|
2023-12-22 |
2025-06-26 |
Institut National de la Santé et de la Recherche Médicale |
Affitins for the treatment of cancer
|
|
US20250215087A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg depleting agent
|
|
WO2025155607A1
(en)
|
2024-01-16 |
2025-07-24 |
Genentech, Inc. |
Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
|
|
WO2025174933A1
(en)
|
2024-02-14 |
2025-08-21 |
Genentech, Inc. |
Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
|
|
US20250269052A1
(en)
|
2024-02-27 |
2025-08-28 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibody drug conjugates
|
|
US20250361320A1
(en)
|
2024-02-27 |
2025-11-27 |
Bristol-Myers Squibb Company |
Anti-ceacam5 antibodies and uses thereof
|
|
WO2025210123A1
(en)
|
2024-04-03 |
2025-10-09 |
Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical composition for treating cancers
|
|
WO2025210175A1
(en)
|
2024-04-04 |
2025-10-09 |
Centre National De La Recherche Scientifique |
Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
|
|
WO2025213154A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
|
|
WO2025210571A1
(en)
|
2024-04-05 |
2025-10-09 |
Astrazeneca Ab |
Treatment of limited-stage small-cell lung cancer with pd-l1 inhibitors
|
|
WO2025219330A1
(en)
|
2024-04-15 |
2025-10-23 |
Institut National de la Santé et de la Recherche Médicale |
Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
|
|
WO2025228998A1
(en)
|
2024-04-30 |
2025-11-06 |
Institut National de la Santé et de la Recherche Médicale |
Use of hdac4 inhibitors for the treatment of melanoma
|
|
WO2025232879A1
(en)
|
2024-05-10 |
2025-11-13 |
Cytocares (Shanghai) Inc. |
Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
|